

1 **ONECUT2 restricts Microfold cell numbers in the small intestine;** 2 **a multi-omics study**

3
4 Maria V. Luna Velez^{1, *}, Hannah K. Neikes^{1, 4}, Rebecca R. Snabel^{2, 4}, Yarah Quint¹, Chen Qian³, Aniek
5 Martens¹, Gert Jan C. Veenstra², Michael R. Freeman³, Simon J. van Heeringen^{2, *}, Michiel Vermeulen^{1, *}.

6
7 ¹ Department of Molecular Biology, Radboud University Nijmegen, Faculty of Science, Radboud Institute
8 for Molecular Life Sciences, Oncode Institute, Nijmegen, 6525 AJ, The Netherlands.

9 ² Department of Molecular Developmental Biology, Radboud University Nijmegen, Faculty of Science,
10 Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 AJ, The Netherlands.

11 ³ Department of Surgery, Division of Cancer Biology, Cedars-Sinai Medical Center, Los Angeles, California,
12 90048, USA.

13 ⁴ These authors contributed equally to this work.

14 * To whom correspondence should be addressed. Tel: +31 243610562; Email:

15 michiel.vermeulen@science.ru.nl

16 Correspondence may also be addressed to: Maria V. Luna Velez. Email: v.luna-velez@science.ru.nl and

17 Correspondence may also be addressed to: Simon J. van Heeringen. Email:

18 s.vanheeringen@science.ru.nl

19

20

21

22 **Abstract**

23 Microfold (M) cells reside in the intestinal epithelium of Peyer's patches. Their unique ability to take up
24 and transport antigens from the intestinal lumen to the underlying lymphoid tissue is key in the
25 regulation of the gut-associated immune response. Here, we applied a (single-cell) multi-omics approach
26 to investigate the molecular mechanisms that drive M cell differentiation in mouse small intestinal
27 organoids. We generated a comprehensive profile of chromatin accessibility changes and transcription
28 factor dynamics during *in vitro* M cell differentiation, allowing us to uncover numerous cell type-specific
29 regulatory elements and associated transcription factors. Single-cell RNA sequencing resulted in the
30 identification of an M cell precursor population. Our new computational tool SCEPIA determined that
31 these precursor cells were characterized by high expression of and motif activity for the transcription
32 factor ONECUT2. Subsequent perturbation experiments revealed that ONECUT2 acts downstream of the
33 RANK/RANKL signalling to support Enterocyte differentiation and restrict M cell lineage specification *in*
34 *vitro* and *in vivo*, thereby regulating mucosal immunity. This study provides a useful blueprint for future
35 investigations of cell fate switches in the intestinal epithelium.

36

37 **Keywords**

38 ONECUT2, RANK/RANKL, Enterocytes, Microfold cells, mouse small intestine

39

40

41

42

43

44 **Background**

45 The Peyer's patches (PP) are focal points within the small intestine, constituted by an organized
46 lymphoid follicle and an overlying follicle-associated epithelium (FAE) (1,2). The FAE is a one-cell-thick
47 layer composed mainly of Enterocytes and specialized epithelial cells called Microfold or M cells (1). M
48 cells are important for enteral uptake and transport of various commensal and pathogenic
49 microorganisms across the epithelial cell layer and to the subepithelial dome (3–6), where immune cells
50 take on a defensive or tolerogenic response (1,7). Like all other cell lineages in the small intestine, M
51 cells derive from intestinal stem cells (ISC) residing in the bottom of the intestinal crypts (8), however
52 only a small percentage of ISC commit to the M cell lineage, making M cells one of the least abundant
53 cell types in the small intestine (9,10). The polarization of M cells to PP and their low abundance reflect
54 tightly regulated mechanisms restricting the commitment of progenitor cells into M cells, but it is
55 precisely the low number of M cells that has made difficult the study of these mechanisms *in vivo*.

56

57 Intestinal organoids or “miniguts” are *in vitro* models capable of self-organizing into epithelial structures
58 that molecularly, phenotypically and functionally resemble *in vivo* intestinal tissue (9,11). Minor
59 modifications of the intestinal organoid culture medium can generate cell type-enriched organoids that
60 can be used to decipher the molecular mechanisms that drive ISC fate (12,13). The receptor activator of
61 nuclear factor κ B (RANK) and its ligand (RANKL) were originally described for their key role in the
62 induction of M cell differentiation (14,15). The addition of recombinant RANKL to the conventional
63 intestinal organoid culture medium induces the differentiation of functional M cells *in vitro* (8), allowing
64 the study of the fundamental signalling regulating M cell lineage specification.

65

66 In this study, we used a multi-omics framework on RANKL-treated mouse small intestinal organoids to
67 define the gene-regulatory mechanisms underlying M cell differentiation. Changes in the morphology of

68 organoids upon RANKL treatment were correlated to differences in protein levels, gene expression,
69 histone modification and chromatin accessibility. By integrating bulk and single-cell RNA-sequencing
70 data we were able to untangle complex gene-regulatory networks contributing to the M cell lineage
71 specification in the intestine. Our findings led to the identification of an M cell precursor cluster, where
72 the one cut domain family member 2 (ONECUT2) acts as a negative regulator of M cell lineage
73 commitment in organoids and in the mouse small intestine.

74

75

76 **Results**

77 **Generation of M cell-enriched mouse small intestinal organoids**

78 *In vivo*, RANKL is expressed by MAdCAM-1⁺ mesenchymal cells beneath the FAE, functioning as M cell
79 inducers by directly interacting with RANK-expressing progenitor epithelial cells (16,17). To mimic this
80 mechanism *in vitro*, organoid culture medium was supplemented with recombinant RANKL for 6 days.
81 Upon treatment, organoids acquired a cyst-like phenotype with wide, expanded villi regions and
82 expression of glycoprotein 2 (GP2) in the apical membrane of a few cells (Fig. 1a and b). GP2 is an
83 endocytic receptor for microorganisms and a marker for mature M cells (9,18). Our mouse small
84 intestinal organoids carry a GFP reporter cassette at the locus of the leucine-rich repeat G-protein-
85 coupled receptor (*Lgr5*) gene (19), a marker for ISC (20), which allowed us to visualize LGR5⁺ ISC in our
86 organoid cultures. Concomitant to the increase in GP2 signal, RANKL treatment led to a reduction of
87 LGR5 expression when compared to control organoids growing in conventional organoid culture
88 medium (Fig. 1b). To evaluate the efficiency of M cell enrichment, flow-cytometry analysis was
89 performed. In control conditions, the number of ISC and M cells was roughly 20% and <0.1%,

90 respectively (Fig. 1c). Treatment with RANKL achieved a 4x increase in the number of M cells consistent
91 with what is found *in vivo* (9,21) and an almost 50x decrease of ISCs (Fig. 1c).

92 In line with these findings, other known markers of M cells such as *Anxa5*, *Ccl20*, *Pglyrp1*, *Marcks11*, *Ccl6*,
93 *Gp2*, *Tnfaip2*, *Rac2* and *Ccl9* (9,18,22) were significantly upregulated in the RANKL conditions at a
94 transcriptome level, while markers of ISC and other intestinal cell types showed opposite dynamics (Fig.
95 1d). To evaluate whether our *in vitro* model recapitulated *in vivo* tissue, whole-transcriptome changes
96 induced upon RANKL-treatment were compared to cell type-specific intestinal signatures generated
97 from a recently published single-cell survey of the mouse small intestine (9). The M cell and the Tuft cell
98 gene signatures were significantly enriched under RANKL conditions, while the Paneth cell, ISC and
99 Goblet cell signatures were enriched in control conditions (Fig. 1e). In addition, the M cell-enriched
100 organoids were significantly enriched for genes involved in immune cell regulation but depleted in those
101 associated with cell cycle and DNA replication (Fig. 1f), reflecting the physiological role of M cells.
102 Together, these findings support the use of our *in vitro* model for the study of intestinal M cell
103 differentiation with the potential of generating data of *in vivo* relevance.

104

105 **RANKL-induced transcriptional regulation**

106 A significant dynamic transcript expression in 314 transcription factors was observed upon RANKL
107 treatment in mouse small intestinal organoids ($p_{adj} < 0.05$). A fold change cut-off of ≥ 1 identified 45
108 and 55 transcription factors significantly upregulated in RANKL-treated and control organoids,
109 respectively. Among those enriched in RANKL conditions we found *Relb*, *Spib* and *Sox8*, known drivers of
110 M cell differentiation (23–25) (Fig. 2a). A prerequisite for transcription factor-mediated activity is an
111 accessible chromatin, which is characterized by the presence of the H3K27ac modification, which marks
112 active enhancers and, to a lesser extent, promoters (26). We used ATAC-sequencing and ChIPmentation

113 to profile chromatin accessibility and the H3K27ac modification in the control and RANKL-treated
114 organoid cultures. A total of 55,055 accessible sites were detected in the RANKL and control sequencing
115 datasets, which were used to identify genomic locations that undergo a significant change in H3K27ac
116 levels between both conditions. At these sites, we identified 93 and 123 motifs enriched in the RANKL
117 and control conditions, respectively, further supporting an active regulatory role for 216 differentially
118 expressed transcription factors (Fig. 2b).

119 To obtain cell type-specific transcriptional regulation profiles across time, single-cell RNA-sequencing
120 analysis was performed in RANKL-treated organoids harvested at different time points during treatment.
121 In total, 6,636 cells were grouped into 20 clusters, which expressed markers from the absorptive or
122 secretory lineages, or markers distinctive of ISC and daughter transit-amplifying cells (TA) (Fig. 2c,
123 Additional file 1: Fig. S1a and Additional file 2: Table S1). Time seemed to separate cell clusters into two
124 main partitions (Fig. 2d). One partition, with cells generated within the first five days of treatment,
125 included cells expressing absorptive lineage makers (cluster 12, 13 and 17), a cell cluster expressing
126 known M cell markers such as *Anxa5*, *Ccl20*, *Pglyrp1*, *Rac2*, *Serpinb1a* and *Ccl9* (cluster 12) and clusters
127 expressing *Id3*, a marker for TA cells (cluster 2, 3, 7 and 10). A second time partition was constituted by
128 cells originating from day 6 to day 9 (experimental end point), marked by the recovery of *Lgr5*
129 expression and an increase in the number of secretory cells (Fig. 2d). *Mki67*, a marker of cell
130 proliferation, seemed to be evenly distributed between cells from both partitions. In agreement with
131 this, EdU labelling on RANKL-treated organoids showed that day 3 M cell-enriched organoids displayed a
132 high number of LGR5⁻, proliferative cells (EdU-labelled), whereas day 6 organoids had proliferative and
133 LGR5⁺ cells solely at crypt bottoms (Additional file 1: Fig. S1b).

134 This time-resolved single-cell transcriptome data was suitable for RNA velocity calculations (27), an
135 analysis in which spliced and unspliced RNA abundance is used to infer a 'direction of change' and
136 predict the future state for each cell in a two-dimensional space. With the aim of unravelling the

137 mechanisms driving M cell differentiation, we further narrowed analyses to cell clusters generated
138 within the first five days of RANKL treatment. RNA velocity results suggested that day 0 *Lgr5*⁺/*Mki67*⁺
139 cells (cluster 14) generated *Lgr5*/*Mki67*⁺ cells characterised by high *Ccnb2* expression (cluster 3) and
140 that these cells turned in time into non-proliferative *Id3*⁺ cells (*i.e.* cluster 2) (Fig. 2e, Additional file 2:
141 Table S1). This process resembled the generation of TA cells from ISC observed *in vivo* (28). Interestingly,
142 cluster 17, characterised by *Aldob* expression and originated from a second day 0 cluster (cluster 13),
143 was shown as a precursor of *Spib*⁺ M cells (cluster 12) (Fig. 2e, Additional file 2: Table S1). In agreement
144 with these findings, clusters originating from cluster 13 (group of interest 1 or GOI1) displayed
145 transcriptional regulatory units or ‘regulons’ (29) for the transcription factors NFKB2, RELB, SPIB and
146 SOX8, well-established drivers of M cell differentiation. GOI1 also included regulons for HNF4G, ZBTB7B,
147 RXRA and RARA, regulators of the absorptive lineage (12,13,30) (Fig. 2f). In contrast, group of interest 2
148 (GOI2) presented regulons of transcription factors previously associated with cell cycle control and
149 crypt-villus maintenance such as MYC, E2F1 and E2F3 (31), and TEAD2, TEAD4 and SOX9 which regulate
150 TA expansion (32,33). A total of 358 regulons supported the identity of cells from GOI1 and GOI2, from
151 which a motif for 56 of these transcription factors was found within an accessible genomic region and
152 significantly enriched by H3K27ac upon RANKL treatment (*p*_{adj} < 0.05) based on our bulk integrative
153 analysis (Fig. 2f, highlighted in red). Collectively, our bulk and single-cell sequencing data defined the
154 transcriptional and cellular responses to RANKL treatment in our organoid model and allowed the
155 identification of a proposed M cell precursor cell population, cluster 17.

156

157 **ONECUT2 signalling in M cell precursor cell population**

158 To predict transcription factor motif activity from single cell RNA-sequencing data, we designed a novel
159 computational tool called SCEPIA (Single Cell Epigenome-based Inference of Activity) (34). By using

160 computationally inferred epigenomes of single cells, SCEPIA can identify transcription factors that
161 determine cellular states. In total, 81 transcription factors showed substantial motif activity within our
162 single cell dataset, like *Pax4* and *Neurog3* in cells of Enteroendocrine cell identity (cluster 15), *Runx1* in
163 Tuft cells (cluster 19), or *Spib* in M cells (cluster 12) (Additional file 2: Table S2). From those transcription
164 factors highly expressed within GO11 (cluster 6, 12, 13 and 17) *Hnf4g*, *Klf5*, *Onecut2* and *Tcf7l2* were the
165 top four with the highest positive correlation between transcript expression and motif activity (Fig. 3a,
166 Additional file 2: Table S2). The hepatocyte nuclear factor 4 gamma (HNF4G) is a key driver of Enterocyte
167 cell differentiation (12,30). The krüppel-like factor 5 (KLF5) is a zinc-finger transcription factor expressed
168 in both ISC and TA cells (35–37) while the one cut domain family member 2 (ONECUT2) transcription
169 factor is decreased in LGR5⁺ ISC (38). The transcription factor 7-like 2 (TCF7L2) is a known downstream
170 effector of the WNT pathway, expressed along the entire crypt-villus axis (39). All four transcription
171 factors have been shown to be essential for proper differentiation of the embryonic intestinal
172 epithelium (35,40–43), but their role in the modulation of gene expression during M cell differentiation
173 was thus far unknown.

174 To define the context for HNF4G-, KLF5-, ONECUT2- and TCF7L2-mediated transcriptional regulation, a
175 differential gene-regulatory network was built using ANANSE (44). Different to our integrative approach,
176 ANANSE takes into account the transcription factor target gene expression in addition to transcription
177 factor expression and H3K27ac and chromatin accessibility profiles to build a differential gene-
178 regulatory network in RANKL over control conditions. A total of 15371 transcription factors and target
179 genes constituted the gene-regulatory networks for HNF4G, KLF5, ONECUT2 and TCF7L2 (Additional file
180 2: Table S3). Interestingly, upon RANKL treatment, ONECUT2-binding motifs were found enriched in
181 active regulatory elements from both *Tcf7l2* and *Klf5* (Additional file 2: Table S3), proposing ONECUT2 as
182 an upstream regulator of TCF7L2 and KLF5-mediated transcriptional activity.

183 ONECUT2 forms part of the cut homeobox family of transcription factors and in mammals this family
184 also includes ONECUT1 and ONECUT3 proteins (45–47). These three proteins have been shown to have
185 a unique as well as an overlapping transcriptional output (48). To determine whether the enrichment for
186 the ONECUT2-binding motifs determined by SCEPIA and ANANSE was specific for the ONECUT2
187 transcription factor, we performed a gene-set enrichment analysis (GSEA) with signatures unique for
188 each cut homeobox protein. Only the ONECUT2 gene signature was shown to be significantly enriched
189 upon RANKL treatment (Fig. 2b). Leading-edge (highly enriched) genes from the ONECUT2-specific
190 signature encode proteins associated with the epithelial membrane, as well as transport and
191 metabolism (Additional file 2: Table S4), in line with previous reports about the ONECUT2 signalling in
192 the mouse small intestine (41). We, then performed ChIP-sequencing analysis using a ONECUT2-specific
193 antibody. A total of 7261 ONECUT2 peaks were identified in the RANKL condition whereas binding of
194 ONECUT2 was almost absent in control condition (Additional file 2: Table S5). Among others, upon
195 RANKL treatment, ONECUT2 was found significantly bound (FDR < 0.05) to active chromatin regions
196 upstream of *Tcf7l2*, *Klf5* and *Hnf4g* and of 167/364 ANANSE-predicted ONECUT2 target genes
197 (Additional file 2: Table S5). This result places ONECUT2 as a master regulator in the GOI1. ANANSE also
198 identified motifs for 21 transcription factors within *Onecut2* enhancer regions, among which those for
199 RELB and NFKB2 binding, the latter having the highest predicted interaction score (Fig. 3c). Consistently,
200 *Onecut2* was found part of the regulon of RELB (Additional file 2: Table S6). Heterodimer formation
201 between RELB and the NFKB2 p52 subunit is known to be required for transcriptional activation of *Spib*
202 and *Sox8* (22), proposing the involvement of the RELB-p52 dimer in the regulation of *Onecut2*
203 expression.

204 To observe the process of M cell lineage commitment in more detail, we performed an unsupervised
205 trajectory analysis in the RANKL-treated cell populations from the GOI1. Cells were ordered based on
206 transcriptome expression and plotted as a function of pseudotime (Fig. 3d). This analysis showed that a

207 subset of cells within precursor cluster 17, corresponding to day 0 (Additional file 1: Fig. S1c), gives rise
208 to three cell populations, characterized by high expression of *Spib*, *Hnf4g* or *Klf5* (Fig. 3d). This is
209 consistent with our experimental time points, where the *Spib*⁺ cell population (M cells) was shown to
210 differentiate earlier, followed by the *Hnf4g*⁺ and later the *Klf5*⁺ cell populations (Additional file 1: Fig.
211 S1c). We, next investigated how the genes from the *Onecut2* regulatory network organized along the
212 differentiation trajectories. For this, we included the ONECUT2 targets determined by ChIP sequencing
213 and ANANSE-predicted *Onecut2* drivers, and only transcription factors that were differentially expressed
214 within RANKL-treated cells clusters of the GOI1. Including *Onecut2*, the expression of 26 transcription
215 factors was found to be pseudotime-dependent (Additional file 2: Table S7). To illustrate their
216 contribution to each pseudotime branch, co-expressed genes were further grouped into modules that
217 co-regulate across the cell clusters (Fig. 3e, Additional file 2: Table S7). *Spib*, *Nfe2l1* and *Pparg* were
218 assigned to modules of genes expressed at high levels in cluster 12, while *Klf5*, *Id2*, *Klf10*, *Bhlhe40*,
219 *Nr3c1*, *Pten* and *Isx* were part of modules of genes highly expressed in cluster 6. *Creb3l2*, *Creb3l3*, *Hnf4g*
220 and other genes belonging to the ONECUT2 transcriptional output were assigned to cluster 17 modules.
221 Remarkably, *Nfkb2*, *Relb* and *Onecut2* shared the same expression module (Additional file 2: Table S7),
222 with genes in common upregulated in cluster 17, supporting the proposed regulatory mechanism of
223 *Onecut2* expression by the RELB/p52 axis. Collectively, these analyses showed that precursor cells within
224 cluster 17 give rise to cluster 6, 12 and a second subcluster of 17 which based on their transcriptome
225 profile fit with a TA, M cell and Enterocyte identity, respectively.

226

227 **ONECUT2 restricts M cell lineage specification**

228 To investigate the functional consequences of the ONECUT2 protein on M cell differentiation, organoid
229 cultures were treated with the ONECUT2 inhibitor CSRM617. This compound was designed to

230 specifically bind to the ONECUT2 homeodomain (HOX), thereby inhibiting DNA binding and ONECUT2-
231 mediated transcriptional activation (49). CSRM617 alone had little, if any, effect on the morphology of
232 organoids when compared to control conditions (Fig. 4a). In contrast, addition of CSRM617 to RANKL
233 medium greatly affected the phenotype previously observed with RANKL treatment, resulting in small-
234 lumen organoids with angular crypts (Fig. 4a). Consistent with the observed phenotype, CSRM617 alone
235 did not affect much the transcriptome profile, compared to control conditions (Additional file 1: Fig.
236 S2a). Co-treatment with RANKL and CSRM617 compared to RANKL alone led to a significant
237 downregulation ($p_{adj} < 0.05$) of 4317 genes, which included 1150 ONECUT2 target genes (Fig. 4b).
238 Together, these results indicate that ONECUT2 signalling in mouse small intestinal organoids is RANKL-
239 dependent.

240 Given the fact that *Onecut2* was shown as a master regulator of GO11, we hypothesized that inhibition
241 of ONECUT2 genomic functions would have a negative effect on M cell differentiation. Strikingly,
242 however, co-treatment with CSRM617 and RANKL resulted in an increase in the number of GP2⁺ cells
243 (Fig. 4c). Effectively, co-treatment with CSRM617 resulted in a significant enrichment of the overall M
244 cell signature from our single-cell dataset (Fig. 4d). These results indicated that ONECUT2 exerts an
245 inhibitory effect in RANKL-induced M cell differentiation *in vitro*.

246 We, next assessed the transcriptome profile of RANKL-treated cell populations from GO11 in single cells
247 from organoids co-treated with RANKL and CSRM617 (Additional file 1: Fig. S2b). The transcriptome
248 profile of precursor cluster 17 was almost completely lost in the co-treatment single-cell dataset (Fig.
249 4e), possibly reflecting an absolute induction toward the M cell lineage and supporting the role of
250 ONECUT2 in the maintenance of cluster 17. The co-treatment also resulted in the loss of 147 regulons
251 that were previously identified in RANKL-alone conditions, 48 of them corresponded to ONECUT2 target
252 genes (Additional file 1: Fig. S2c, highlighted on red). It also included transcription factors characteristic
253 of GO12, a group of cell clusters largely composed by *Mki67*⁺/*Lgr5*⁻ proliferative cells (Fig. 2d and f,

254 Additional file 1: Fig. S2c). This is in agreement with the loss of the cystic phenotype that was observed
255 in organoids subjected to RANKL treatment (Fig. 4a) and stresses a switch in cellular programs, from a
256 balanced proliferative/differentiated state to an overdriven differentiation program.

257 If the induction of M cell differentiation by RANKL and CSRM617 co-treatment inhibited that of
258 Enterocyte cluster 17 cells we wondered whether the induction of Enterocyte cell differentiation would
259 then inhibit M cell number. In a previous study, we established the culture medium conditions for the
260 enrichment of Enterocytes in mouse small intestinal organoids, the so-called EN medium (12).
261 Interestingly, the HNF4G but not ONECUT2 signature was found significantly upregulated in EN
262 conditions (Fig. 4f). Remarkably, the addition of RANKL to EN medium upregulated the levels of *Oncut2*,
263 *Hnf4g*, and ONECUT2 targets *Klf5* and *Klf6*, and markedly lowered the number of M cells compared to
264 regular RANKL medium (Fig. 4g and 4h). These experiments demonstrated that the ONECUT2 induction
265 of Enterocyte differentiation and inhibition on M cell lineage specification *in vitro* is dependent on the
266 RANK/RANKL signalling.

267

268 **ONECUT2 limits M cell number in Peyer's patches**

269 To investigate the physiological relevance of our findings *in vivo*, mice were treated with CSRM617 as
270 described in Additional file 1: Fig. S2d. Because RANKL is naturally highly expressed within the Peyer's
271 patches (PP) of the small intestine (16,17), we assessed the protein expression of M cell markers in this
272 tissue. Reassuringly, treatment with CSRM617 increased the number of SPIB⁺ and GP2⁺ cells in the PP,
273 compared to control treatment (Fig. 5a). Consistently, treatment induced an upregulation of M cell
274 markers *Spib*, *Gp2* and *Tnfaip2* in the small intestine tissue, all of which increased in time (Fig. 5b). While
275 the expression of the transcription factor and M cell driver *Spib* was significantly downregulated
276 immediately after termination of the treatment, mature M cell markers *Gp2* and *Tnfaip2* (9) remained

277 expressed at levels higher than in control conditions even after a week of recovery from treatment,
278 likely reflecting the turnover of M cells (Fig. 5a). Treatment achieved downregulation of ONECUT2-
279 targeted genes *Klf5*, *Klf6*, *Hoxb8*, *Foxn3* and *Tfcp2l1*, similar to the effect observed in organoids (Fig. 5c).
280 ONECUT2 inhibition also led to a reduction in the levels of *Hnf4g* (Fig. 5c), but did not affect the
281 transcript levels of markers from other cell types in the small intestine such as *Dclk1* (Tuft), *Defa6*
282 (Paneth) or *Reg4* (Enteroendocrine) (Additional file 1: Fig. S2e), reiterating on the RANKL-dependent role
283 of ONECUT2 to cells of the absorptive lineage.

284 The organized lymphoid follicle underlying the PP are sites for the generation of IgA⁺ B cells and the
285 production of secretory IgA (SIgA) (7), the body's first line of defence in the resistance against toxins and
286 bacterial and viral infections (50). SIgA production is a consequence of M cell immune-related functions
287 and its expression level reflects M cell numbers (15,51,52). Because ONECUT2 inhibition led to an
288 increase in the number of M cells, we investigated to what extent this could affect the levels of SIgA. To
289 this aim, we run ELISA experiments for targeted detection of mouse IgA in faecal samples of treated
290 mice. Faecal SIgA levels increased over time after treatment with CSRM617 and dropped after a week
291 receiving control treatment (Fig. 5d). These levels correlated with the expression of *Ccr9* and *Itgb7*,
292 markers of IgA⁺ B cells (53) (Fig. 5e). The weight of mice treated with CSRM617 was comparable to that
293 of littermate controls and no difference was observed between genders (Additional file 1: Fig. S2f).
294 Based on these observations, we conclude that ONECUT2 restricts the M cell number in PP, indirectly
295 regulating B cell functions and SIgA production.

296

297 **Discussion**

298 In this study, we set out to use multiple omics platforms and diverse computational tools to define the
299 molecular landscape of M cell-enriched organoids in an unbiased, comprehensive manner. By combining

300 the strengths of bulk sequencing methods (*e.g.* small input material, sequencing depth) and single-cell
301 approaches (*e.g.* characterisation of small populations, trajectory inference tools) to generate time-
302 resolved data, we untangled complex gene-regulatory networks that contribute to the M cell lineage
303 specification.

304 Our integrative approach revealed that ONECUT2 acts as a negative regulator of M cell differentiation *in*
305 *vitro* and *in vivo*, by supporting Enterocyte differentiation in a RANKL-dependent manner. Under RANKL
306 conditions, blockage of ONECUT2-mediated transcriptional activity led to an increase in the number of
307 M cells (*Spib*⁺, *Anxa5*⁺) and a decrease in the Enterocytes cell population (*Hnf4g*⁺, *Alpi*⁺). A low M cell
308 number has been proposed to be needed for the maintenance of proper intestinal barrier function and
309 to prevent an over-reactive immune response (54), and ONECUT2 expression could be one of the
310 mechanisms ensuring this. The elevated expression of IgA⁺ B cell markers and high levels of intestinal
311 SIgA we observed *in vivo* upon ONECUT2 inhibition supports this hypothesis. Moreover, the expression
312 of *Klf5*, a transcription factor predicted to be target of ONECUT2 has been shown to protect mice against
313 murine colitis by activating the JAK-STAT signalling pathway (55).

314 *Oncut2* was one of the transcription factors with the highest expression and motif activity in a cell
315 population precursor for M cells, Enterocytes and a TA cell population. Expression of *Oncut2* was
316 correlated with that of *Nfkb2* and *Relb*, transcription factors responsible for transcriptional activation of
317 *Spib* and *Sox8* (22) and which expression in the small intestine are restricted to follicle-associated crypts
318 (56). Motifs from both transcription factors were found within *Oncut2* enhancers, supporting a
319 potential role for RELB-p52 dimer in the transcriptional regulation of *Oncut2*.

320 We have created a new computational tool we named SCEPIA (34) and validated it for its capacity to
321 predict transcription factor motif activity from single cell RNA-sequencing data, to identify those
322 transcription factors, like ONECUT2, that are determinant of cellular states. Likewise, we have generated

323 several resource datasets that can be used to perform different analyses, for instance, to uncover
324 additional regulatory axes underlying RANKL signalling, or as reference datasets of the chromatin
325 remodelling and transcriptional responses to ONECUT2-transcription factor activity. In human and
326 mouse, ONECUT2 is highly expressed in the liver, pancreas, small intestine and the nervous system. In
327 addition, ONECUT2 expression is significantly associated with poor clinical outcome in diverse type of
328 cancers such as prostate, breast, gastric, colon, clear cell renal, brain, and lung cancer (49). The systemic
329 administration of the ONECUT2 inhibitor CSRM617 in mice, described in this study, generated tissue
330 resources that can be used to study the many diverse roles of the ONECUT2 in different tissues, in the
331 context of health and disease.

332

333 **Limitations of study**

334 Mouse small intestinal organoids are a powerful and versatile *in vitro* model, which resembles the *in*
335 *vivo* intestinal epithelium at a cellular, molecular and functional level, thereby facilitating the study of
336 complex biological processes such as stem cell renewal and cell differentiation. Though organoids
337 typically consist of several distinct epithelial cell types, cultures rarely include other non-epithelial cells
338 (*i.e.* stromal, mesenchymal or immune cells), which represent a source of factors that can be important
339 for the cellular maturation and/or differentiation of epithelial cells. For M cells, beside MAdCAM-1⁺
340 mesenchymal cells, which express RANKL, lympho-epithelial cell interactions such as those with B cells
341 have been shown to play a role in the induction of M cell differentiation (57,58). In addition, it has been
342 shown that M cell differentiation can be induced in response to external stimuli such as a pathogen
343 infection (56) but incorporating all these factors in a culture with organoids can be challenging. Thus, it
344 remains to be answered whether pathogen-induced signalling would overrule inhibitory M cell
345 differentiation signals such as those mediated by ONECUT2, uncovered in this study.

346

347 **Conclusions**

348 In this study we have shown that the ONECUT2 transcription factor acts downstream of RANK/RANKL
349 signalling to orchestrate Enterocyte and M cell lineage specification *in vitro* and *in vivo*. Our perturbation
350 studies demonstrated that ONECUT2 in fact restricts M cell differentiation within the FAE which has an
351 impact in mucosal immunity as the levels of SIgA, the body's first line immune defence, is a direct
352 consequence of M cell function.

353 While the focus of this study resulted in the discovery of a transcription factor as a regulator of intestinal
354 M cell differentiation, the computational workflows described here can serve as an outline for future
355 endeavours aimed at deciphering gene expression regulation of stem cell fate and differentiation in the
356 intestine and other multicellular tissues. Over the last years, different computational tools have been
357 designed to model complex gene-regulatory networks and to facilitate the integration of multiple data
358 types (*i.e.* transcriptome, genome) of different resolutions (*i.e.* bulk, single-cell). Though each tool is
359 informative on its own, we found that the integration of all these was essential for the elaboration of
360 the conclusions presented in this study.

361

362 **Methods**

363 ***In vivo* CSRM617 experiments**

364 Both male and female C57BL/6 mice (5 weeks old) were purchased from Charles River. After arriving,
365 the mice were quarantined for one week prior to the study. Four treatment groups were designed for
366 the *in vivo* experiments with the ONECUT2 inhibitor CSRM617 (Additional file 1: Fig. S2d). Each
367 treatment group contained 3 male and 3 female C57BL/6 mice of 6-6.5 weeks of age. Briefly, 6 mice

368 received 50 mg/kg⁻¹ CSRM617 (Cedars Sinai Medical Center) for 7 days and 6 mice for 14 days. A
369 recovery group consisted of 6 mice treated with 50 mg/kg⁻¹ CSRM617 (Cedars Sinai Medical Center)
370 for 7 days followed by 7 days treatment with phosphate buffered saline (PBS) and 0.2% dimethyl
371 sulfoxide (DMSO, Sigma-Aldrich). Lastly, a control group treated with PBS and 0.2% DMSO for 7 days was
372 included. All treatments were performed by intraperitoneal injection. Body weight was tracked 3 times
373 per week. For ELISA experiments, faecal samples were collected 30 minutes before sacrifice of the mice.
374 A total of 100 mg of mice faeces were dissolved in 1 mL of 1x PBS with 1% protease inhibitors (Thermo
375 Scientific) and vortexed for 15 minutes at 4°C. Supernatant was isolated after centrifugation at 12,000 x
376 g for 10 min and stored at -80°C until IgA measurements. The small intestines of 3 mice per treatment
377 group (1 female and 2 males) were gently rinsed twice with 1x PBS and collected in individual tubes
378 containing 1.2 mL of RNeasy Lysis Solution (Qiagen), and frozen at -80°C until being
379 processed for RNA isolation. The small intestines from the remaining 3 mice of each treatment group (2
380 female and 1 male) were collected to prepare separate formalin-fixed paraffin-embedded tissue blocks
381 following the “swiss roll” method (59).

382

383 **Culture of mouse small intestinal organoids**

384 The mouse small intestinal organoids used in the current study were generated by isolating LGR5⁺ adult
385 stem cells from the gut of a female *Lgr5*^{GFPDTR/+} mouse and culturing them in a well-defined semi-solid
386 culture medium supplemented with essential growth factors (11). The female *Lgr5*^{GFPDTR/+} mouse was
387 generated by replacing the first coding exon of *Lgr5* with a cassette containing the coding sequence for
388 the enhanced green fluorescent protein (EGFP) linked in frame to the human diphtheria toxin receptor
389 (DTR) gene cDNA (19).

390 Small intestinal organoids derived from a female *Lgr5*^{GFPDTR/+} mouse (19) were cultured as described
391 previously (11). Briefly, organoids were grown embedded in a mix of 90% ice-cold RGF BME Type 2

392 PathClear (Cultrex, R&D Systems) and 10% Dulbecco's modified Eagle's Medium/Ham's F12 (Gibco), in a
393 humidified atmosphere at 37°C and 5% CO₂. For maintenance and control conditions organoids grew in
394 ENR medium which contained advanced Dulbecco's modified Eagles Medium/F12 (Gibco) supplemented
395 with 1x Penicillin-Streptomycin (Gibco), 10 mM HEPES (Gibco), and 1x GlutaMAX Supplement (Gibco), 1x
396 B27 (Gibco), 1.25 mM N-acetylcysteine (Sigma Aldrich), 50 ng/mL mEGF (Gibco), 10% final volume
397 NOGGIN conditioned medium, 5% final volume R-SPONDIN1 conditioned medium. For maintenance,
398 organoids were split by mechanical dissociation using a Pasteur pipette every 5 days and the culture
399 medium was refreshed every other day (11). For microfold (M) cell enrichment, organoids were cultured
400 in ENR supplemented with 3 μM CHIR99021 (Axon) and 1.5 mM valproic acid (Sigma) for three days,
401 followed by one day in ENR medium. Afterwards, treatment with 100 ng/mL of recombinant mouse
402 TRANCE (RANKL) (BioLegend) was done for 6 or 9 days, alone or in combination with 40 μM CSRM617
403 Hydrochloride (Sigma-Aldrich). For EN experiments, RANKL was added to EN medium described
404 previously (12). ENR medium alone or in combination with 40 μM CSRM617 were used as controls.
405 Medium was refreshed every three days.

406

407 **Bulk RNA-sequencing sample preparation**

408 After treatment, organoids from three independent differentiation experiments were harvested using
409 Organoid Harvesting Solution (Cultrex) according to manufacturer's protocol. Pellets were snap frozen
410 and stored at -80 °C until being processed for RNA isolation using the RNeasy RNA extraction kit
411 (Qiagen) with *DnaseI* treatment using RNase-Free DNase (Qiagen). Total RNA (1 μg per replicate) was
412 used for library preparations using the KAPA RiboErase Kit (HMR) (Roche) following manufacturer's
413 protocol. A fragmentation step was carried out for 6.5 minutes at 94°C and 7 μM NextFlex DNA barcodes
414 (PerkinElmer) were used for adapter ligation. Libraries were amplified using 6 amplification cycles.
415 Library concentration was measured using the dsDNA Fluorescence Quantification Assays (DeNovix), and

416 library size was determined using the BioAnalyzer High Sensitivity DNA Kit (Agilent Technologies) in a
417 BioAnalyzer instrument (Agilent). Sequencing was performed using an Illumina NextSeq 500, and 42-bp
418 paired-end reads were generated.

419

420

421 **Bulk ATAC-seq sample preparation**

422 After harvesting of organoids from three independent differentiation experiments, pellets were
423 cryopreserved in Recovery Cell Culture Freezing Medium (Gibco) at -80°C until being processed for
424 ATAC-seq. ATAC-seq libraries were prepared following an adapted protocol from
425 Buenrosto *et al.* and Corces *et al.* (60,61). In brief, 50,000 cells per replicate were lysed in 50 µl of ice-
426 cold ATAC Resuspension Buffer (RSB) containing 0.1% IGEPAL (Sigma), 0.1% Tween-20 (Sigma), and
427 0.01% Digitonin (Sigma) for 3 minutes on ice. Lysates were resuspended with 1 mL of cold ATAC-RSB
428 containing 0.1% Tween-20 (Sigma) and nuclei were pelleted by centrifugation at 500 rcf for 10 minutes
429 at 4°C in a fixed angle centrifuge. Nuclei were tagmented for 6 minutes at 37°C with in-house made *Tn5*
430 enzyme while shaking at 650 rpm. The tagmentation reaction was stopped with stop buffer (44 mM
431 EDTA, 131 mM NaCl, 0.3% SDS, and 600 µg/ml proteinase K as final concentration). Genomic DNA was
432 purified using 2x AMPure XP beads (Beckman Coulter) and subsequently amplified by PCR using KAPA
433 HiFi Hotstart Ready Mix and Nextera Index Kit (Illumina) primers. Lastly, a reverse-phase 0.65x AMPure
434 XP beads (Beckman Coulter) DNA purification step was done, followed by 1.5x AMPure XP beads
435 (Beckman Coulter) purification. Library concentration was measured using the dsDNA Fluorescence
436 Quantification Assays (DeNovix), and library size was determined using the BioAnalyzer High Sensitivity
437 DNA Kit (Agilent Technologies). DNA libraries were sequenced with an Illumina NextSeq 500 at a read
438 length of 38 bp.

439

440 **ChIPmentation sample preparation**

441 Following harvesting, organoids were crosslinked with 1 % formaldehyde in 1x PBS shaking at 650 rpm
442 for 10 minutes at room temperature, and glycine (125 mM final concentration) was added to quench
443 the reaction. After a washing step with 1x ice-cold PBS, cell pellets were snap frozen and stored at -80°C
444 until being processed for ChIPmentation. A total of 250,000 cells per replicate were lysed in a buffer
445 containing 20 mM HEPES pH 7.6, 1% SDS, 1x Protease Inhibitor Cocktails (Roche). Chromatin was
446 sheared using the medium setting of the Biorupter Pico (Diagenode) with 6 cycles (20 seconds on/30
447 seconds off) to achieve fragments between 200 and 600 bp. Samples were then spun at 13,000 rpm for
448 5 minutes at room temperature and supernatant containing fragmented chromatin was used for
449 ChIPmentation as described by Schmidl *et al.* (62) with the modifications published in Lindeboom *et al.*
450 (12). Briefly, before starting the immunoprecipitation, we saved 1% of the input material of either
451 control or RANKL-treated organoids and stored it at 4°C until further processing (tagmentation). Then,
452 chromatin of each replicate was incubated with 1 µg of antibody against H3K27ac (Diagenode,
453 C15410196, RRID:AB_2637079) or 1 µg of antibody against ONECUT2 (Proteintech, 21916-1-AP,
454 AB_2848180) in dilution buffer (1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8, 167 mM NaCl, 1x
455 Protease Inhibitor Cocktail (Roche)), rotating overnight at 4°C. Antibody-bound chromatin was purified
456 using protein A and protein G Dynabeads (Invitrogen) followed by two washing steps with increasing
457 concentration of NaCl and one washing step with TE buffer as described before (12). Tagmentation of
458 immunoprecipitated and input chromatin was performed with in-house generated *Tn5* enzyme for 10
459 minutes at 37°C while shaking at 550 rpm, followed by washing steps with decreasing amounts of NaCl
460 and soap (12). Lastly, samples were de-crosslinked with 20 µg of proteinase K (Sigma) in elution buffer
461 (0.5% SDS, 300 mM NaCl, 5 mM EDTA, 10 mM Tris pH 8) for 1 hour at 55°C and 1,000 rpm shaking
462 followed by an overnight incubation at 65°C and 1,000 rpm shaking. The eluted, tagmented chromatin
463 was treated with 10 µg proteinase K (Sigma) for 1 additional hour at 55°C and purified using 2x AMPure

464 XP beads (Beckman Coulter). The generated libraries were amplified using the KAPA HiFi Hotstart Ready
465 Mix and Nextera Index Kit 1 (i7) and 2 (i5) primers (Illumina). Amplified libraries were purified using a
466 0.65x AMPure XP beads (Beckman Coulter) followed by a 1.8x AMPure XP beads (Beckman Coulter)
467 purification. Library concentration was measured using the dsDNA Fluorescence Quantification Assays
468 (DeNovix), and library size was determined using the BioAnalyzer High Sensitivity DNA Kit (Agilent
469 Technologies). DNA libraries were sequenced with an Illumina NextSeq 500, and 38-bp paired-end reads
470 were generated.

471 **Single-cell RNA-sequencing sample preparation**

472 After harvesting, organoids were dissociated using TrypLE (Gibco). Viable single cells were sorted in 384-
473 well PCR plates (Bio-Rad) using the Becton Dickinson Aria (BD Biosciences) sorter with a 100 µm nozzle,
474 based on forward and side scatter gating. Prior to sorting, plates were primed with oligos (5'-3')
475 containing the T7 promoter, a 5' Illumina adapter, unique molecular identifiers (UMIs), a unique cell
476 barcode and the oligo-(dT)N for tagging of individual mRNA molecules within each cell (63). Immediately
477 after sorting, plates were centrifuged for 2 minutes at 1,200 x g and 4°C and stored at -80°C until library
478 preparation. Libraries were prepared using a modified CEL-Seq2 protocol (64). In brief, a micro-
479 dispenser machine Nanodrop II (BioNex) was used to dispense in each well the ERCC spike-in control
480 RNAs (1:50,000, Invitrogen), reagents used for the reverse transcription (RT) reaction such as
481 Superscript II (Invitrogen) and RNasein Plus (Promega), and for the second strand synthesis such as *E.*
482 *coli* DNA polymerase and *E. coli* DNA ligase (New England Biolabs). Second strand synthesis was done in
483 the presence of *E. coli* RNase H (Invitrogen). Double stranded cDNA from each well was pooled together
484 and purified with AMPure XP beads (Beckman Coulter). *In vitro* transcription was performed overnight
485 according to the Ambion MegaScript IVT kit protocol (Invitrogen), followed by an exonuclease digestion
486 step with EXOI/rSAP-IT (Applied Biosystems). The amplified RNA was later fragmented and cleaned up
487 using AMPure XP beads (Beckman Coulter). Samples were then subjected to library RT using random

488 octamers (63) and to cDNA amplification thereafter using the Phusion High-Fidelity DNA Polymerase
489 (New England Biolabs). A forward primer sequence against the 5' Illumina adapter (63) and a reverse
490 primer sequence against the octamers overhang incorporated during RT were added to the
491 amplification mix. The reverse primer contained an Illumina 3' adapter sequence and an index sequence
492 to uniquely identify each library (NextFlex DNA barcodes, PerkinElmer). Libraries were purified and
493 quantified using the dsDNA Fluorescence Quantification Assays (DeNovix) and fragment sizes were
494 assessed with the BioAnalyzer High Sensitivity DNA Kit (Agilent Technologies). The libraries were
495 sequenced on an Illumina NextSeq 500, and 63-bp paired-end reads were generated.

496

497 **Bulk RNA-sequencing analysis**

498 Paired-end reads were aligned to the mouse mm10 genome using the STAR RNAseq-aligner v2.7.9a (65),
499 with `-sjdbOverhang` set to 100. Mapped reads were counted with HTSeq-count v0.13.5 (66) and the
500 following settings: `-r pos -s reverse -t exon`. Normalization and \log_2 -transformation of data was done
501 using the DESeq2 package v1.34.0 (67). Genes with an adjusted p-value < 0.05 were considered
502 statistically significant. Expression heatmaps were created with ComplexHeatmap v2.10.0 (68).

503

504 **Bulk ATAC-sequencing analysis**

505 Preprocessing of reads was done automatically with atac-seq workflow from the seq2science pipeline
506 v.0.3.1 (69). In short, reads were trimmed using fastp v0.20.1 (70) and aligned to the mouse mm10
507 genome using bwa-mem v0.7.17 (71). Mitochondrial reads, multipmapper reads, mapped reads below a
508 minimum mapping quality of 20 or reads inside the ENCODE blacklist (72) were filtered out. Reads were
509 shifted +4 bp/-5 bp on the positive/negative strand to account for the *Tn5* inserting bias. Duplicate
510 reads were removed with picard MarkDuplicates v2.21.2 (73). Peaks were called using macs2 v2.2.7

511 (74), with the settings `--shift -100 --extsize 200 --nomodel --keep-dup 1 --buffer-size 10000` in BAM
512 mode. Being paired-end reads, the option `macs2_keep_mates` was set to true.

513

514 **ChIPmentation analysis**

515 The ChIPmentation reads were processed with the chip-seq workflow from `seq2science v.0.3.1` (69),
516 taking the 1% input samples of either control or RANKL-treated organoids as background for peak
517 calling. The workflow of preprocessing, alignment, deduplication and quality filtering was similar to the
518 workflow described for the ATAC-seq analysis, but without shifting sequencing reads in alignment or
519 during peak calling.

520 For the ONECUT2 ChIPmentation, we used `Diffbind` (75) (v.3.4.11) to identify differentially bound
521 genomic loci between RANKL- and control-treated organoids, with an FDR-cutoff of 0.05. For
522 visualization of the results, we used the `coverage_table` function from `GimmeMotifs` to generate a table
523 of log-transformed counts for these differential regions for RANKL and control samples. The top 250
524 peaks based on the fold change of RANKL over control were used to generate a ONECUT2 ChIP gene set.

525 Lastly, HNF4G ChIPmentation samples from mouse small intestinal organoids grown in EN medium and
526 control were obtained from GSE114113 (12) and processed with the chip-seq workflow from
527 `seq2science (v.0.7.2)`, without input controls for peak calling. We used `GREAT` (76) to assign each peak to
528 the nearest gene and subsequently defined a EN-specific HNF4G target gene set by selecting genes near
529 peaks from EN-cultured organoids that were not present in the control-samples, and subsequently
530 selecting the top 250 peaks based on the fold change of the peak over background to generate an
531 HNF4G ChIP gene set.

532

533 **Integration and analysis of bulk sequencing data**

534 ATAC-seq peaks generated for each replicate by seq2science, for both control and RANKL-treated
535 conditions, were combined in one peak file using the *combine_peaks* script from the package
536 GimmeMotifs v0.16.0 (77) with the window parameter (-w 4000) (generating roughly 60,000 accessible
537 sites). ChIPmentation alignments, corresponding to the H3k27ac signal, were quantified at these regions
538 using the *coverage_table* function from GimmeMotifs v0.16.0 (77) with a window of 2 kb. Differential
539 H3k27ac signal ($p_{adj} < 0.05$) was defined with the DESeq2 package v1.34.0 (67) and used as input for the
540 tool *gimme maelstrom* to detect differential motifs, without filtering out redundant motifs. A z-score
541 cut-off of > 1.64 and < -1.64 was used to define enriched motifs in either control or RANKL-treated
542 conditions. Motifs were matched to transcription factors with the *gimme motif2factors* conversion table
543 provided by GimmeMotifs (77). Only motifs for which the corresponding transcription factor was
544 differentially expressed ($p_{adj} < 0.05$) in the bulk RNA-seq data were included for visualization in an
545 integrative heatmap, which was generated with ComplexHeatmap v2.10.0 (68).

546

547 **Gene-regulatory network analysis with ANANSE**

548 The *ananse binding* command line tool from ANANSE v0.3.0 (44) was used to predict treatment-specific
549 transcription factors binding profiles, using the ATAC-seq and ChIPmentation outputs from seq2science.
550 Enhancer regions were specified with the combined peak summit file containing identified ATAC-seq
551 peaks from both RANKL-treated and control conditions. The function *ananse network* was run to infer
552 treatment-specific gene-regulatory networks. For this, binding profiles from *ananse binding*, gene-level
553 transcript-per-million (TPM) data for each condition and the mm10 as the genome assembly were used.
554 The mm10 genome assembly was downloaded from UCSC using genomepy v0.9.1 (78). To obtain a
555 gene-level TPM file, reads in the RNA-seq FASTQ files (.fastq) were quantified using the command line
556 tool Kallisto v0.46.2 (79). The prebuild Kallisto index constructed from the Ensemble reference mouse
557 transcriptome GRCm38 was downloaded from <https://github.com/pachterlab/kallisto-transcriptome->

558 [indices/releases](#) and used. Using tximport v1.14.2 (80) the expression of all isoforms corresponding the
559 same gene was summed up and identifiers were changed to gene-level. Lastly, the *ananse influence*
560 function was used to generate a differential gene-regulatory network, based on the difference in the
561 interaction score calculated per factor between RANKL treatment and control conditions. Number of top
562 edges used to define the differential network was set to 500.00 (-i 500_000).

563

564

565 **Analysis of single-cell RNA-sequencing data**

566 Raw FASTQ files were demultiplexed, aligned and annotated to the mouse GRCm38 genome indexed
567 with sequences from the ERCC ExFold RNA Spike-In Mixes (invitrogen), and counted using the
568 kallisto|bustools wrapper kb_pythion v0.26.3 (79,81). Pre-processing and quality control was
569 performed using the Scater package v1.10.1 (82). To exclude low-quality cells from further analysis, any
570 cell with < 500 detected features, < 1,000 total transcripts, > 40% mitochondrial transcripts or > 20%
571 ERCC transcripts were removed from the datasets. Normalization, natural log-transformation, scaling
572 (with “nCount” and “nFeature” as variables to regress), and clustering analysis were performed using
573 Seurat v3.1.5 (83). We determined the 2,000 highly variable genes using the variance stabilizing
574 transformation (VST) method. Dimensionality reduction was performed by principal component analysis
575 (PCA), and was followed by Louvain clustering using the *FindNeighbors* function with the top 30 principal
576 components (PCs) and the *FindClusters* function with a resolution set to 1.6 for the RANKL treatment
577 dataset (21,099 genes across 6,636 cells), and the top 20 PCs and a resolution of 1.5 for the dataset of
578 RANKL and CSRM617 combined treatment (9,257 genes across 1,903 cells). Data was projected in a two-
579 dimensional space using the Uniform Manifold Approximation and Projection (UMAP) method. Label
580 transferring from clusters 6, 12 and 17 from the RANKL treatment dataset (21,099 genes in 820 cells) to
581 clusters 3, 9, 10 and 12 from the dataset of RANKL and CSRM617 combined treatment (9,257 genes in

582 427 cells) was done using the Seurat *FindTransferAnchors* function using the RANKL treatment dataset
583 selected clusters as a reference.

584

585 **Trajectory inference**

586 RNA velocity estimation was done using *velocyto.R* v.0.6 (27). The raw counts corresponding to spliced
587 and unspliced RNA forms for each gene, generated by the *kallisto|bustools* wrapper and stored as
588 separate assays in the Seurat object, were used by *velocyto.R* to create an RNA velocity map. The RNA
589 velocity map was then projected as a grid with arrows onto the UMAP space that was generated by
590 Seurat with the function *show.velocity.on.embedding.cor*.

591 For the pseudotime analysis, raw counts of cells from the Seurat clusters 6, 12 and 17 from the RANKL
592 treatment dataset that passed the Scater quality assessment were processed with the R package
593 *Monocle3* v1.0.0 (84) with default settings. The *preprocess_cds* function of *Monocle3* normalized by log
594 and scaled the data. The function also calculated a low-dimensional space used as input for
595 dimensionality reduction with a UMAP. With the *learn_graph* function, *Monocle3* used a principal
596 graph-embedding procedure based on the SimplePPT algorithm (85,86) to represent on the UMAP the
597 possible paths cells can take as they develop. The pseudotime was calculated across these paths by
598 setting the furthest away cells from cluster 17 as time zero. Lastly, we used *graph_test*, a function based
599 on the Moran's statistical test (87) to define the pseudotime-dependent genes and the
600 *find_gene_modules* function to group these genes into modules based on their co-expression across
601 clusters.

602

603 **Motif activity prediction with SCEPIA**

604 Using SCEPIA v0.5.1 (<https://github.com/vanheeringen-lab/scepia>) a list of transcription factors of
605 interest was established by predicting transcription factor motif activities based on the single-cell RNA-
606 seq data. The normalized and scaled spliced RNA counts and associated annotation generated with
607 Seurat (v3), including highly variable genes and clustering, were exported to an AnnData object in
608 Python v3.9.6. First, H3K27ac profiles were assigned to the single cells using a H3K27Ac reference
609 database. The ENCODE H3K27Ac ChIP-seq database of 121 human cell lines and tissues included in
610 SCEPIA was used as a reference (88,89). The regulatory potential, a summarized, distance-weighted
611 measure of H3K27ac within 100kb of the gene transcription start site, was calculated for every gene,
612 according to Xu *et al.* (44) similar to Wang *et al.* (90). Using the top 2,000 highly variable genes from the
613 scRNA-seq data, cells were matched to H3K27Ac profiles using Ridge regression with the normalized and
614 scaled gene expression level as the response variable and the H3K27Ac regulatory potential as the
615 explanatory variable. The output of this regression was a matrix with per single cell a coefficient for each
616 cell type (single cell x cell type matrix). Only the top 50 scoring cell types (ordered by the mean absolute
617 coefficient over the clusters) were kept and from these the top 10,000 highest variable enhancers,
618 based on the genome-wide H3K27Ac data, were selected for motif activity analysis using the Bayesian
619 Ridge method with GimmeMotifs v0.16.1 (77) resulting in a motif x cell type matrix. The predicted motif
620 coefficients (“motif activity”) for each H3K27Ac reference cell type were combined into single cell motif
621 activities using a dot product of the single cell x cell type matrix and the motif x cell type matrix. Pearson
622 correlations between single cell motif activity and the single cell expression levels of the transcription
623 factors binding the motifs, based on the default database of GimmeMotifs, were calculated, followed by
624 100,000 random permutations to determine a permutation-based p-value. The permutation-based p-
625 value was combined with the p-value of the correlation using Fisher’s method and corrected for multiple
626 testing using the Benjamini-Hochberg correction. From the list of transcription factor-motif

627 combinations, the hits with the highest positive correlation coefficients and an FDR ≤ 0.1 were selected.

628 The *gimme logo* tool from GimmeMotifs (77) was used to generate motif logos.

629

630 **Gene-regulatory network analysis with pySCENIC**

631 Raw counts from the Seurat object were used as input for pySCENIC v0.11.0 (91). First, gene-regulatory
632 networks between transcription factors and putative target genes were inferred with the *grnboost2*
633 function from the Arboreto package v0.1.6 (92) part of pySCENIC, using a mouse transcription factor
634 database available from the TFCat portal through pySCENIC. The *ctx* command kept only transcription
635 factor motifs within 10 kb from the target transcription start site (TSS) and pruned indirect targets from
636 dataset based on *cis*-regulatory cues. For this, the motifs database motifs-v9-nr.mgi-m0.001-o0.0, the
637 *cis*-target databases mm10__refseq-r80__500bp_up_and_100bp_down_tss.mc9nr and mm10__refseq-
638 r80__10kb_up_and_down_tss.mc9nr were used. As a default option, only transcriptional regulatory
639 units (regulons) with a positive correlation between the expression of a transcription factor and its
640 targets were used for further analysis. The area under the curve (AUC) scores (regulon activity) were
641 calculated for every cell using the *auceff* function with default options and later averaged per Seurat
642 cluster. Data was visualized using *gplots* v3.1.1 (93).

643

644 **Gene-set enrichment analysis**

645 Gene-set enrichment analysis (GSEA) was performed using the *fgsea* package v1.19.3 (94). Mouse *in vivo*
646 intestinal cell-type gene sets were extracted from (9) by selecting the top 250 differentially expressed
647 genes with an FDR (Q, max) < 0.05 and a mean natural-log fold change > 0.5 . To create the ONECUT1-,
648 ONECUT2- and ONECUT3-specific signatures, RNA-seq data from Data ref: (48) was downloaded using
649 the download-fastq workflow from seq2science and re-analyzed with DESeq2 package v1.34.0 (67). Top
650 250 differentially expressed genes ($\text{padj} < 0.05$), unique for each overexpression condition and with a

651 \log_2 fold change > 0.5 over control were used to create the gene sets. Lastly, genes with a p_{adj} < 0.05
652 and a mean natural-log fold change > 0.5 were used to create the cluster 12 gene set from the RANKL
653 treatment single-cell dataset. For all experiments, ranked files with \log_2 fold change expression values
654 (p_{adj} < 1) were subjected to GSEA.

655

656 **Real-time semi-quantitative RT-qPCR**

657 Mice small intestines were washed with 1X PBS to remove excess of RNAlater (Invitrogen) and 15-20 mg
658 of tissue were lysed with 1 mL of TRIzol (Ambion) and incubated overnight at -20°C. At the next day,
659 tissue was homogenized using RNase-free pestles, 14G (1.6 mm) and 21G (0.8 mm) needles. Lysates
660 were centrifuged for 5 minutes at 12,000 × g and 4°C. Supernatant was processed for RNA isolation
661 following TRIzol manufacturer's instructions. After this, a total of 30 µg of isolated total RNA per
662 replicate was purified with the Quick-RNA Microprep Kit (Zymo research) and 1 µg of purified RNA was
663 used for cDNA synthesis using the iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR analysis was
664 performed using the iQ SYBR Green Supermix (Bio-Rad) in a CFX96 Real-Time system (Bio-Rad). Crossing-
665 point (Cp) values were determined by the CFX Manager software version 3.0 (Bio-Rad). Expression levels
666 of Gapdh were used for normalization. Relative gene expression levels were calculated according to
667 Pfaffl *et al.* (95). Primers for RT-qPCR can be found in Additional file 2: Table S8.

668

669 **Flow-cytometry analysis**

670 After harvesting, organoids were dissociated using TrypLE (Gibco). Organoid cells were counted using
671 the Muse Cell Analyzer (Merck) and a total of 100,000 viable cells per well and in triplicates per
672 treatment were seeded in conic v bottom 96-well plates (greiner bio-one). After washing with 1% PBA
673 buffer (1% Bovine serum albumin (Sigma) in 1x PBS), cells were incubated with rat anti-mouse GP2
674 antibody (MBL International Corporation, D278-5, RRID:AB_11160946) in a 1:10 dilution in 100 µl of 1%

675 PBA buffer per well. Incubation was done for 30 minutes at 4°C and was followed by three washing steps
676 with 1% PBA buffer. All washing steps were done by centrifugation of 3 minutes at 200 x g and 4°C. Cells
677 were lastly fixed with 1% formaldehyde for 20 minutes at room temperature and in dark. After removal
678 of the formaldehyde solution and one washing step, cells were resuspended in 1% PBA before being
679 analyzed in the MACSQuant Analyzer 10 (Miltenyi Biotec). FITC signal (LGR5⁺ cells) and PE signal (GP2⁺
680 cells) were detected in cell population selected based on forward and side scatter gating, and
681 pseudocolor density plots were generated using FlowJo v10 (BD Biosciences).

682

683 **Enzyme-linked immunoassay (ELISA)**

684 Measurement of secretory IgA (SIgA) in mouse faeces samples after treatment with the ONECUT2
685 inhibitor CSRM617 Hydrochloride (Sigma-Aldrich) or PBS control was done using the SIgA Mouse
686 Uncoated ELISA kit (Invitrogen) following manufacturer's instructions. Faecal supernatants were diluted
687 to a final assay concentration of 10 ng/mL. A solution of 2N H₂SO₄ was used to stop the reaction and
688 the concentration of SIgA was deduced from the standard curve made with the IgA standards provided
689 by the kit.

690

691 **Live imaging and immunohistochemistry**

692 Whole-mount immunofluorescence staining of organoids was performed in conical bottom polystyrene
693 12 mL tubes (Greiner). Briefly, after harvesting of organoids, these were transferred to the round-
694 bottom 15 mL tubes pre-coated with 1% PBA. Two washing steps with ice-cold 1x PBS were carried out
695 by gently resuspending the organoids and letting them sit at the bottom of the tubes before discarding
696 supernatant. Organoids were then fixed in 4% formaldehyde for 15 minutes followed by two washing
697 steps with ice-cold 1x PBS. Permeabilization of organoids was done with 0.5% Triton in 1x PBS for 30
698 minutes. This was followed by two washing steps and a quenching step with 20 mM Glycine in 1x PBS for

699 30 minutes. Unspecific signal was then blocked with 1% PBA for 30 minutes. Three washing steps with
700 1% PBA were done before overnight incubation with primary antibodies rat anti-GP2 (MBL International
701 Corporation, D278-3, RRID:AB_10598188), diluted 1:100 in blocking solution. To prevent organoids from
702 sitting at the bottom of the tube, incubation was carried out in a shaker at 45 rpm. Organoids were then
703 washed three times with 1x PBS and incubated with Alexa Fluor 647 Goat anti-Rat IgG secondary
704 antibody (Invitrogen, A-21247, RRID:AB_141778) diluted 1:400 in blocking solution, for 1.5 hours in a
705 shaker at 45 rpm and covered from light. Antibodies were washed out three times with 1x PBS. Staining
706 with methanolic phalloidin (Thermo Fisher Scientific) diluted in blocking solution was performed for 20
707 minutes and followed by three washing steps. Finally, nuclear counterstaining with Hoechst (50 µg/mL,
708 brand) was done for 20 minutes. Organoids were washed three times more and mounted on 22 mm-
709 diameter glass bottom dishes (WillCo Wells) with Ibbidi mounting medium (Ibbidi). For live microscopy,
710 EDU labelling was performed using the Click-iT EdU Imaging Kits (Invitrogen) and following
711 manufacturer's protocol on organoids embedded in single BME domes, seeded on 8-well chamber slides
712 (Ibbidi).

713 Formalin-fixed paraffin-embedded mice small intestines were sectioned 4 µm-thick and mounted on
714 Superfrost Plus slides (Thermo Fisher Scientific). Deparaffination was performed overnight at 37°C and
715 re-hydration steps were followed by heat-induced epitope retrieval with boiling sodium citrate (pH9) for
716 10 minutes. Blocking of endogenous peroxidase activity was done with 1% H₂O₂ for 15 minutes and was
717 followed by blocking of unspecific binding with 2% PBA for 1 hour. GP2 or SPIB primary antibodies
718 (1:100) were incubated overnight in 1% PBA. For detection of GP2 protein, sections were incubated for
719 30 minutes with biotinylated Rabbit IgG anti-rat (H+L) secondary antibody (Vector Laboratories, BA-
720 4001, RRID:AB_10015300) 1:200 in 1% PBA and 30 minutes with an ABC mix solution from the
721 VECTASTAIN Elite ABC Reagent kit (Vector Laboratories, PK-6101, RRID:AB_2336820). To reveal the
722 reaction, sections were incubated with Bright DAB solution (Immunologic) for 5 minutes followed by 10-

723 seconds nuclear counterstaining with Hematoxylin, dehydration and mounting with Permount mounting
724 media (Fisher Chemical). Overnight incubation with sheep anti-SPIB antibody (R&D Systems, AF7204,
725 RRID:AB_10995033) diluted 1:100 in blocking solution was followed by a 1-hour incubation with Alexa
726 Fluor 568 Donkey anti-Sheep IgG (H+L) secondary antibody (Invitrogen, A-21099, RRID:AB_2535753)
727 diluted 1:400 in blocking solution. Slides were mounted with Fluoromount-G with DAPI mounting
728 medium (Invitrogen). Except for first antibody incubations, all steps for immunohistochemistry were
729 done at room temperature.

730

731 **Image Analysis**

732 Live-cell and three-dimensional images were captured with a Leica TCS SP8 microscope (Leica). For live
733 imaging the organoids were held at 37°C. Organoids were imaged in XYZ mode using an HCX PL APO
734 63x/1.2 water immersion objective. Post-acquisition analysis of fluorescence signal was performed
735 manually using ImageJ version 1.53c (96). Bright-field and fluorescence imaging of mouse tissue sections
736 was carried out in the Axio Observer 7 microscope with Sample Finder AI (Zeiss) using a 20x/0.8
737 objective.

738 Brightfield images of organoids were fed to ImageJ and processed using the OrgM macro to measure
739 circularity (97) defined by the formula $4\pi(\text{area}/\text{perimeter}^2)$. For analysis thresholding mode was enable
740 and watershed mode was disabled. Circularity was plotted for each treatment.

741

742 **Statistical analysis**

743 Statistical difference in organoid circularity obtained by ImageJ, fluorescence signal detected by Flow
744 cytometry, relative expression obtained by RT-qPCR or fluorescence signal corresponding to IgA levels
745 were calculated using an unpaired t test in the Prism software version 5.03 (GraphPad). Bars graphs

746 represent the mean \pm SEM. The n numbers are provided in figure legends or in the Methods section
747 corresponding to each technique. A p-value of < 0.05 was considered statistically significant and $p < 0.05$
748 was represented by one star (*), $p < 0.01$ was represented by two stars (**) and $p < 0.001$ was
749 represented by three stars (***)).

750

751 **Declarations**

752 **Ethics approval and consent to participate**

753 For the mouse experiments, all experimental protocols and procedures were approved by the
754 Institutional Animal Care and Use Committee (IACUC) at Cedars-Sinai Medical Center and the
755 Comparative Medicine Department. All relevant ethical regulations, standards, and norms were
756 rigorously adhered to.

757

758

759 **Consent for publication**

760 Not applicable.

761

762 **Availability of data and materials**

763 All sequencing data generated in this study (*i.e.*, FASTQ files) as well as processed data (*i.e.* raw and
764 normalized counts) have been deposited at GEO and are publicly available in the SuperSeries record
765 GSEXXXXXX which links to SubSeries for ATAC-sequencing (GSEXXXXXX), ChIP-sequencing (GSEXXXXXX),
766 bulk RNA-sequencing (GSEXXXXXX) and single-cell RNA-sequencing data (GSEXXXXXX).

767 The code to carry out the analysis described in this study with SCEPIA v0.5.1 is provided as Jupyter
768 Notebooks and available at https://github.com/Rebecza/Mcell_differentiation. Original code for SCEPIA
769 (34) (<https://github.com/vanheeringen-lab/scepia>) can be found at [https://github.com/vanheeringen-](https://github.com/vanheeringen-lab/scepia/blob/master/tutorials/scepia_tutorial.ipynb)
770 [lab/scepia/blob/master/tutorials/scepia_tutorial.ipynb](https://github.com/vanheeringen-lab/scepia/blob/master/tutorials/scepia_tutorial.ipynb).

771 Any additional information required to reanalyse the data reported in this paper is available from Dr.
772 Michiel Vermeulen (michiel.vermeulen@science.ru.nl) upon reasonable request.

773

774 **Competing interests**

775 CSRM617 is under review for patent protection submitted by Cedars Sinai Medical Center (Application
776 number: 17/145,152).

777

778 **Funding**

779 This work was supported by an ERC Consolidator Grant to MV (771059). The Vermeulen lab is part of the
780 Oncode Institute, which is partly funded by the Dutch Cancer Society (KWF). *In vivo* studies were funded
781 by the NCI (1R01CA220327) and the US Department of Defense (PC180541).

782

783 **Author contributions**

784 M.V.L.V. and M.V. conceived the study and contributed to the experimental design. M.V.L.V., H.N., A.M.
785 and C.Q. performed experiments. M.V.L.V., H.N., R.R.S. and Y.Q. performed data analysis. C.Q. and
786 M.R.F. carried out mice treatment. S.J.v.H. created the computational tool SCEPIA. M.V.L.V. prepared
787 the manuscript. H.N., R.R.S., Y.Q., C.Q., A.M., G.J.C.V., M.R.F., S.J.v.H. and M.V. revised and approved the
788 final version of the manuscript.

789

790 **Acknowledgments**

791 The authors would like to thank the members of the Vermeulen laboratory for valuable suggestions and
792 troubleshooting. We thank Marijke Baltissen and Lieke Lamers from the Sequencing facility from the
793 department of Molecular Biology from Radboud University (RU) for their help with next generation
794 sequencing, also Rob Woestenenk and Tom van Oorschot from the Radboud Technology Center for Flow
795 Cytometry, and Laura Wingens from the department of Molecular Developmental Biology at RU for their
796 training and assistance with fluorescence-activated cell sorting and flow cytometry. We would like to
797 thank Marieke Willemse from the Radboud Technology Center for Microscopy for the training and
798 assistance with microscopy. The authors also thank the Pathology laboratory at the Cedars Sinai Medical
799 Center and Birgitte Walgreen from the department of Rheumatology at Radboudumc for the technical
800 support with tissue preparation and immunohistochemistry, and Yanpeng Xing from the laboratory of
801 Michael Jung at the University of California, Los Angeles, who synthesized the CSRM617 compound for
802 the *in vivo* studies. Lastly, the authors thank Jos Smits and the members from the van Heeringen group
803 at RU for their support and fruitful discussions.

804

805 **Authors' information**

806 Information from corresponding authors: v.luna-velez@science.ru.nl, @VickyLunaVelez (M.V.L.V.),
807 s.vanheeringen@science.ru.nl, @svheeringen (S.J.v.H.) michiel.vermeulen@science.ru.nl,
808 @LabVermeulen (M.V.).

809

810

811

812

813

814

815

816

817

818

819

820

821 **References**

- 822 1. Kraehenbuhl JP, Neutra MR. Epithelial M cells: differentiation and function. *Annu Rev Cell Dev*
823 *Biol.* 2000;16:301–32.
- 824 2. Corr SC, Gahan CCGM, Hill C. M-cells: origin, morphology and role in mucosal immunity and
825 microbial pathogenesis. *FEMS Immunol Med Microbiol.* 2008 Jan;52(1):2–12.
- 826 3. Amerongen HM, Weltzin R, Farnet CM, Michetti P, Haseltine WA, Neutra MR. Transepithelial
827 transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. *J Acquir Immune*
828 *Defic Syndr.* 1991;4(8):760–5.
- 829 4. Amerongen HM, Weltzin R, Mack JA, Winner LS 3rd, Michetti P, Apter FM, et al. M cell-mediated
830 antigen transport and monoclonal IgA antibodies for mucosal immune protection. *Ann N Y Acad*

- 831 Sci. 1992;664:18–26.
- 832 5. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and
833 immunization. *Cell*. 1996 Aug;86(3):345–8.
- 834 6. Gonzalez-Hernandez MB, Liu T, Payne HC, Stencel-Baerenwald JE, Ikizler M, Yagita H, et al.
835 Efficient norovirus and reovirus replication in the mouse intestine requires microfold (M) cells. *J*
836 *Virology*. 2014 Jun;88(12):6934–43.
- 837 7. Fagarasan S, Honjo T. Regulation of IgA synthesis at mucosal surfaces. *Curr Opin Immunol*. 2004
838 Jun;16(3):277–83.
- 839 8. de Lau W, Kujala P, Schneeberger K, Middendorp S, Li VSW, Barker N, et al. Peyer’s patch M cells
840 derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured “miniguts”.
841 *Mol Cell Biol*. 2012 Sep;32(18):3639–47.
- 842 9. Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, et al. A single-cell survey of the small
843 intestinal epithelium. *Nature*. 2017 Nov;551(7680):333–9.
- 844 10. Hase K, Ohshima S, Kawano K, Hashimoto N, Matsumoto K, Saito H, et al. Distinct gene
845 expression profiles characterize cellular phenotypes of follicle-associated epithelium and M cells.
846 *DNA Res an Int J rapid Publ reports genes genomes*. 2005;12(2):127–37.
- 847 11. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem
848 cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature*. 2009
849 May;459(7244):262–5.
- 850 12. Lindeboom RG, van Voorthuijsen L, Oost KC, Rodriguez-Colman MJ, Luna-Velez M V, Furlan C, et
851 al. Integrative multi-omics analysis of intestinal organoid differentiation. *Mol Syst Biol*. 2018
852 Jun;14(6):e8227.

- 853 13. Wester RA, van Voorthuijsen L, Neikes HK, Dijkstra JJ, Lamers LA, Frölich S, et al. Retinoic acid
854 signaling drives differentiation toward the absorptive lineage in colorectal cancer. *iScience*. 2021
855 Dec;24(12):103444.
- 856 14. Taylor RT, Patel SR, Lin E, Butler BR, Lake JG, Newberry RD, et al. Lymphotoxin-independent
857 expression of TNF-related activation-induced cytokine by stromal cells in cryptopatches, isolated
858 lymphoid follicles, and Peyer's patches. *J Immunol*. 2007 May;178(9):5659–67.
- 859 15. Knoop KA, Kumar N, Butler BR, Sakthivel SK, Taylor RT, Nochi T, et al. RANKL is necessary and
860 sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. *J*
861 *Immunol*. 2009 Nov;183(9):5738–47.
- 862 16. Nagashima K, Sawa S, Nitta T, Tsutsumi M, Okamura T, Penninger JM, et al. Identification of
863 subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. *Nat Immunol*. 2017
864 Jun;18(6):675–82.
- 865 17. Nagashima K, Sawa S, Nitta T, Prados A, Koliaraki V, Kollias G, et al. Targeted deletion of RANKL in
866 M cell inducer cells by the Col6a1-Cre driver. *Biochem Biophys Res Commun*. 2017
867 Nov;493(1):437–43.
- 868 18. Kobayashi A, Donaldson DS, Kanaya T, Fukuda S, Baillie JK, Freeman TC, et al. Identification of
869 novel genes selectively expressed in the follicle-associated epithelium from the meta-analysis of
870 transcriptomics data from multiple mouse cell and tissue populations. *DNA Res an Int J rapid*
871 *Publ reports genes genomes*. 2012 Oct;19(5):407–22.
- 872 19. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, et al. A reserve stem cell population in
873 small intestine renders Lgr5-positive cells dispensable. *Nature*. 2011 Sep;478(7368):255–9.
- 874 20. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem

- 875 cells in small intestine and colon by marker gene Lgr5. *Nature*. 2007 Oct;449(7165):1003–7.
- 876 21. Boonekamp KE, Dayton TL, Clevers H. Intestinal organoids as tools for enriching and studying
877 specific and rare cell types: advances and future directions. *J Mol Cell Biol*. 2020 Aug;12(8):562–
878 8.
- 879 22. Kobayashi N, Takahashi D, Takano S, Kimura S, Hase K. The Roles of Peyer’s Patches and
880 Microfold Cells in the Gut Immune System: Relevance to Autoimmune Diseases. *Front Immunol*.
881 2019;10:2345.
- 882 23. Kanaya T, Hase K, Takahashi D, Fukuda S, Hoshino K, Sasaki I, et al. The Ets transcription factor
883 Spi-B is essential for the differentiation of intestinal microfold cells. *Nat Immunol*. 2012
884 Jun;13(8):729–36.
- 885 24. Kimura S, Yamakami-Kimura M, Obata Y, Hase K, Kitamura H, Ohno H, et al. Visualization of the
886 entire differentiation process of murine M cells: suppression of their maturation in cecal
887 patches. *Mucosal Immunol*. 2015 May;8(3):650–60.
- 888 25. Kimura S, Kobayashi N, Nakamura Y, Kanaya T, Takahashi D, Fujiki R, et al. Sox8 is essential for M
889 cell maturation to accelerate IgA response at the early stage after weaning in mice. *J Exp Med*.
890 2019 Apr;216(4):831–46.
- 891 26. Creighton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al. Histone H3K27ac
892 separates active from poised enhancers and predicts developmental state. *Proc Natl Acad Sci U S*
893 *A*. 2010 Dec;107(50):21931–6.
- 894 27. La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, et al. RNA velocity of single
895 cells. *Nature*. 2018 Aug;560(7719):494–8.
- 896 28. Potten CS. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. *Philos*

- 897 Trans R Soc London Ser B, Biol Sci. 1998 Jun;353(1370):821–30.
- 898 29. Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, et al. SCENIC:
899 single-cell regulatory network inference and clustering. *Nat Methods*. 2017 Nov;14(11):1083–6.
- 900 30. Chen L, Toke NH, Luo S, Vasoya RP, Fullem RL, Parthasarathy A, et al. A reinforcing HNF4-SMAD4
901 feed-forward module stabilizes enterocyte identity. *Nat Genet*. 2019 May;51(5):777–85.
- 902 31. Liu H, Tang X, Srivastava A, Pécot T, Daniel P, Hemmelgarn B, et al. Redeployment of Myc and
903 E2f1-3 drives Rb-deficient cell cycles. *Nat Cell Biol*. 2015 Aug;17(8):1036–48.
- 904 32. Guillermin O, Angelis N, Sidor CM, Ridgway R, Baulies A, Kucharska A, et al. Wnt and Src signals
905 converge on YAP-TEAD to drive intestinal regeneration. *EMBO J*. 2021 Jul;40(13):e105770.
- 906 33. Li Q, Sun Y, Jarugumilli GK, Liu S, Dang K, Cotton JL, et al. Lats1/2 Sustain Intestinal Stem Cells and
907 Wnt Activation through TEAD-Dependent and Independent Transcription. *Cell Stem Cell*. 2020
908 May;26(5):675-692.e8.
- 909 34. van Heeringen SJ. vanheeringen-lab/scepia: Version 0.5.1 [Internet]. 2021 [cited 2022 Jan 14].
910 Available from: <https://doi.org/10.5281/zenodo.4892888#YeHaJLW6bs8.mendeley>
- 911 35. Kim C-K, He P, Bialkowska AB, Yang VW. SP and KLF Transcription Factors in Digestive Physiology
912 and Diseases. *Gastroenterology*. 2017 Jun;152(8):1845–75.
- 913 36. Nandan MO, Yang VW. The role of Krüppel-like factors in the reprogramming of somatic cells to
914 induced pluripotent stem cells. *Histol Histopathol*. 2009 Oct;24(10):1343–55.
- 915 37. Nandan MO, Ghaleb AM, Bialkowska AB, Yang VW. Krüppel-like factor 5 is essential for
916 proliferation and survival of mouse intestinal epithelial stem cells. *Stem Cell Res*. 2015
917 Jan;14(1):10–9.

- 918 38. Nigmatullina L, Norkin M, Dzama MM, Messner B, Sayols S, Soshnikova N. Id2 controls
919 specification of Lgr5(+) intestinal stem cell progenitors during gut development. *EMBO J.* 2017
920 Apr;36(7):869–85.
- 921 39. Gregorieff A, Pinto D, Begthel H, Destrée O, Kielman M, Clevers H. Expression pattern of Wnt
922 signaling components in the adult intestine. *Gastroenterology.* 2005 Aug;129(2):626–38.
- 923 40. McConnell BB, Yang VW. Mammalian Krüppel-like factors in health and diseases. *Physiol Rev.*
924 2010 Oct;90(4):1337–81.
- 925 41. Dusing MR, Maier EA, Aronow BJ, Wiginton DA. Onecut-2 knockout mice fail to thrive during
926 early postnatal period and have altered patterns of gene expression in small intestine. *Physiol*
927 *Genomics.* 2010 Jun;42(1):115–25.
- 928 42. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, et al. Depletion of epithelial
929 stem-cell compartments in the small intestine of mice lacking Tcf-4. *Nat Genet.* 1998
930 Aug;19(4):379–83.
- 931 43. Chen L, Toke NH, Luo S, Vasoya RP, Aita R, Parthasarathy A, et al. HNF4 factors control chromatin
932 accessibility and are redundantly required for maturation of the fetal intestine. *Development.*
933 2019 Aug;146(19).
- 934 44. Xu Q, Georgiou G, Frölich S, van der Sande M, Veenstra GJC, Zhou H, et al. ANANSE: an enhancer
935 network-based computational approach for predicting key transcription factors in cell fate
936 determination. *Nucleic Acids Res.* 2021 Aug;49(14):7966–85.
- 937 45. Lemaigre FP, Durviaux SM, Truong O, Lannoy VJ, Hsuan JJ, Rousseau GG. Hepatocyte nuclear
938 factor 6, a transcription factor that contains a novel type of homeodomain and a single cut
939 domain. *Proc Natl Acad Sci U S A.* 1996 Sep;93(18):9460–4.

- 940 46. Vanhorenbeeck V, Jacquemin P, Lemaigre FP, Rousseau GG. OC-3, a novel mammalian member
941 of the ONECUT class of transcription factors. *Biochem Biophys Res Commun.* 2002
942 Apr;292(4):848–54.
- 943 47. Kropp PA, Gannon M. Onecut transcription factors in development and disease. *Trends Dev Biol.*
944 2016;9:43–57.
- 945 48. van der Raadt J, van Gestel SHC, Nadif Kasri N, Albers CA. ONECUT transcription factors induce
946 neuronal characteristics and remodel chromatin accessibility. *Nucleic Acids Res.* 2019
947 Jun;47(11):5587–602.
- 948 49. Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang W-C, et al. ONECUT2 is a
949 targetable master regulator of lethal prostate cancer that suppresses the androgen axis. *Nat Med*
950 [Internet]. 2018/11/26. 2018 Dec;24(12):1887–98. Available from:
951 <https://www.ncbi.nlm.nih.gov/pubmed/30478421>
- 952 50. Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. *Front Immunol.*
953 2013;4:185.
- 954 51. Martinoli C, Chiavelli A, Rescigno M. Entry route of *Salmonella typhimurium* directs the type of
955 induced immune response. *Immunity.* 2007 Dec;27(6):975–84.
- 956 52. Hashizume T, Togawa A, Nochi T, Igarashi O, Kweon M-N, Kiyono H, et al. Peyer’s patches are
957 required for intestinal immunoglobulin A responses to *Salmonella* spp. *Infect Immun.* 2008
958 Mar;76(3):927–34.
- 959 53. Wilmore JR, Gaudette BT, Gómez Atria D, Rosenthal RL, Reiser SK, Meng W, et al. IgA Plasma Cells
960 Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific
961 Gene Expression Patterns. *Front Immunol.* 2021;12:791095.

- 962 54. Kucharzik T, Lügering N, Rautenberg K, Lügering A, Schmidt MA, Stoll R, et al. Role of M cells in
963 intestinal barrier function. *Ann N Y Acad Sci.* 2000;915:171–83.
- 964 55. Tetreault M-P, Alrabaa R, McGeehan M, Katz JP. Krüppel-like factor 5 protects against murine
965 colitis and activates JAK-STAT signaling in vivo. *PLoS One.* 2012;7(5):e38338.
- 966 56. Tahoun A, Mahajan S, Paxton E, Malterer G, Donaldson DS, Wang D, et al. Salmonella transforms
967 follicle-associated epithelial cells into M cells to promote intestinal invasion. *Cell Host Microbe.*
968 2012 Nov;12(5):645–56.
- 969 57. Golovkina T V, Shlomchik M, Hannum L, Chervonsky A. Organogenic role of B lymphocytes in
970 mucosal immunity. *Science.* 1999 Dec;286(5446):1965–8.
- 971 58. Kernéis S, Bogdanova A, Kraehenbuhl JP, Pringault E. Conversion by Peyer’s patch lymphocytes of
972 human enterocytes into M cells that transport bacteria. *Science.* 1997 Aug;277(5328):949–52.
- 973 59. Moolenbeek C, Ruitenberg EJ. The “Swiss roll”: a simple technique for histological studies of the
974 rodent intestine. *Lab Anim.* 1981 Jan;15(1):57–9.
- 975 60. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for
976 fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and
977 nucleosome position. *Nat Methods.* 2013 Dec;10(12):1213–8.
- 978 61. Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, et al. An
979 improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues.
980 *Nat Methods.* 2017 Oct;14(10):959–62.
- 981 62. Schmidl C, Rendeiro AF, Sheffield NC, Bock C. ChIPmentation: fast, robust, low-input ChIP-seq for
982 histones and transcription factors. *Nat Methods.* 2015 Oct;12(10):963–5.

- 983 63. Gerlach JP, van Buggenum JAG, Tanis SEJ, Hogeweg M, Heuts BMH, Muraro MJ, et al. Combined
984 quantification of intracellular (phospho-)proteins and transcriptomics from fixed single cells. *Sci*
985 *Rep.* 2019 Feb;9(1):1469.
- 986 64. Hashimshony T, Senderovich N, Avital G, Klochendler A, de Leeuw Y, Anavy L, et al. CEL-Seq2:
987 sensitive highly-multiplexed single-cell RNA-Seq. *Genome Biol.* 2016 Apr;17:77.
- 988 65. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-
989 seq aligner. *Bioinformatics.* 2013 Jan;29(1):15–21.
- 990 66. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput
991 sequencing data. *Bioinformatics.* 2015 Jan;31(2):166–9.
- 992 67. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
993 data with DESeq2. *Genome Biol.* 2014;15(12):550.
- 994 68. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in
995 multidimensional genomic data. *Bioinformatics.* 2016 Sep;32(18):2847–9.
- 996 69. van der Sande M, Frölich S, Smits J, Heeringen S van. seq2science [Internet]. 2020 [cited 2022 Jan
997 14]. Available from: <https://doi.org/10.5281/zenodo.4246844#YeHmzee5OAw.mendeley>
- 998 70. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics.*
999 2018 Sep;34(17):i884–90.
- 1000 71. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013 Mar
1001 16 [cited 2022 Jan 14]; Available from: <http://arxiv.org/abs/1303.3997>
- 1002 72. Amemiya HM, Kundaje A, Boyle AP. The ENCODE Blacklist: Identification of Problematic Regions
1003 of the Genome. *Sci Rep.* 2019 Jun;9(1):9354.

- 1004 73. Picard. Picard Toolkit. Broad Institute, GitHub Repository. [Internet]. 2019. Available from:
1005 <https://broadinstitute.github.io/picard/>
- 1006 74. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of
1007 ChIP-Seq (MACS). *Genome Biol.* 2008;9(9):R137.
- 1008 75. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential
1009 oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature.* 2012
1010 Jan;481(7381):389–93.
- 1011 76. McLean CY, Bristol D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional
1012 interpretation of cis-regulatory regions. *Nat Biotechnol.* 2010 May;28(5):495–501.
- 1013 77. Bruse N, Heeringen SJ van. GimmeMotifs: an analysis framework for transcription factor motif
1014 analysis. *bioRxiv* [Internet]. 2018 Jan 1;474403. Available from:
1015 <http://biorxiv.org/content/early/2018/11/20/474403.abstract>
- 1016 78. van Heeringen SJ. genomepy: download genomes the easy way [Internet]. 2017 [cited 2022 Jan
1017 14]. Available from: <https://doi.org/10.5281/zenodo.831969#.YeHrtaT9-t8.mendeley>
- 1018 79. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. *Nat*
1019 *Biotechnol.* 2016 May;34(5):525–7.
- 1020 80. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates
1021 improve gene-level inferences. *F1000Research.* 2015;4:1521.
- 1022 81. Melsted P, Boeshaghi AS, Liu L, Gao F, Lu L, Min KH (Joseph), et al. Modular, efficient and
1023 constant-memory single-cell RNA-seq preprocessing. *Nat Biotechnol* [Internet]. 2021;39(7):813–
1024 8. Available from: <https://doi.org/10.1038/s41587-021-00870-2>

- 1025 82. McCarthy DJ, Campbell KR, Lun ATL, Wills QF. Scater: pre-processing, quality control,
1026 normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics*. 2017
1027 Apr;33(8):1179–86.
- 1028 83. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, et al. Comprehensive
1029 Integration of Single-Cell Data. *Cell*. 2019 Jun;177(7):1888-1902.e21.
- 1030 84. Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, et al. The single-cell transcriptional
1031 landscape of mammalian organogenesis. *Nature*. 2019 Feb;566(7745):496–502.
- 1032 85. Mao Q, Yang L, Wang L, Goodison S, Sun Y. SimplePPT: A Simple Principal Tree Algorithm. In:
1033 Proceedings of the 2015 SIAM International Conference on Data Mining (SDM) [Internet]. Society
1034 for Industrial and Applied Mathematics; 2015. p. 792–800. (Proceedings). Available from:
1035 <https://doi.org/10.1137/1.9781611974010.89>
- 1036 86. Mao Q, Wang L, Tsang IW, Sun Y. Principal Graph and Structure Learning Based on Reversed
1037 Graph Embedding. *IEEE Trans Pattern Anal Mach Intell*. 2017 Nov;39(11):2227–41.
- 1038 87. Moran PAP. Notes on continuous stochastic phenomena. *Biometrika*. 1950 Jun;37(1–2):17–23.
- 1039 88. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human
1040 genome. *Nature*. 2012 Sep;489(7414):57–74.
- 1041 89. Davis CA, Hitz BC, Sloan CA, Chan ET, Davidson JM, Gabdank I, et al. The Encyclopedia of DNA
1042 elements (ENCODE): data portal update. *Nucleic Acids Res*. 2018 Jan;46(D1):D794–801.
- 1043 90. Wang S, Zang C, Xiao T, Fan J, Mei S, Qin Q, et al. Modeling cis-regulation with a compendium of
1044 genome-wide histone H3K27ac profiles. *Genome Res*. 2016 Oct;26(10):1417–29.
- 1045 91. van de Sande B, Flerin C, Davie K, De Waegeneer M, Hulselmans G, Aibar S, et al. A scalable

- 1046 SCENIC workflow for single-cell gene regulatory network analysis. *Nat Protoc.* 2020
1047 Jul;15(7):2247–76.
- 1048 92. Moerman T, Aibar Santos S, Bravo González-Blas C, Simm J, Moreau Y, Aerts J, et al. GRNBoost2
1049 and Arboreto: efficient and scalable inference of gene regulatory networks. *Bioinformatics.* 2019
1050 Jun;35(12):2159–61.
- 1051 93. Warnes G, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. *gplots: Various R*
1052 *programming tools for plotting data.* Vol. 2, R package version. 2005.
- 1053 94. Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set
1054 enrichment analysis. *bioRxiv [Internet].* 2021 Jan 1;60012. Available from:
1055 <http://biorxiv.org/content/early/2021/02/01/060012.abstract>
- 1056 95. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic*
1057 *Acids Res.* 2001 May;29(9):e45.
- 1058 96. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat*
1059 *Methods.* 2012 Jul;9(7):671–5.
- 1060 97. Cai E, Thomas RA. OrgM: A Fiji macro for automated measurement of object area, diameter and
1061 roundness from bright field images. 2019; Available from: <https://github.com/neuroeddu/OrgM>
1062
1063
1064
1065
1066
1067

1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081

1082 **Figure legends**

1083

1084 **Fig. 1.** Generation of M cell-enriched mouse small intestinal organoids. **a** Brightfield images of control
1085 and M cell-enriched (RANKL-treated) organoids, next to graphical representation of their cell type
1086 composition. Microscope magnification is depicted. Graph shows the quantification of organoid
1087 circularity (AU, arbitrary units) and mean \pm SEM. Control n=50 and RANKL n=51. **b** Nucleus (Hoechst), F-
1088 actin (Phalloidin) and GP2 staining and detection of LGR5 signal in control and RANKL-treated organoids.
1089 On the right, orthogonal view on a zoom in image from the RANKL condition is displayed. Dotted lines
1090 show axes intersection point. Microscope magnification is depicted. **c** Representative density plots
1091 depict fluorescent intensities in the FITC (LGR5) and PE (GP2) channels, detected by flow cytometry. The

1092 percentage for each gate population is described. Bar graph represents the mean \pm SEM of the fold
1093 change from at least five differentiation experiments. **d** Heatmap showing the relative change in mRNA
1094 expression upon RANKL treatment compared to control. Known markers of M cells and other intestinal
1095 cell lineages are highlighted. Rows show Z scores of normalized, \log_2 -transformed values from
1096 significantly changing genes ($p_{adj} < 0.05$). **e** Gene-set enrichment analysis showing *in vivo* gene
1097 signatures of mouse small intestine cell lineages from Haber *et al.* (9) enriched in RANKL-treated
1098 organoids compared to control organoids (dark grey). Normalized enrichment score (NES) and p_{adj}
1099 values are described. Signatures enriched in control compared to RANKL condition (light grey) have a
1100 negative NES. **f** Gene-set enrichment analysis showing gene ontology (GO) terms significantly enriched
1101 ($p_{adj} < 0.05$) in control (light grey) and RANKL-treated organoids (dark grey).

1102

1103 **Fig. 2.** RANKL-induced transcriptional regulation. **a** Heatmap showing the relative change in mRNA
1104 expression of transcription factors upon RANKL treatment compared to control. Known markers of M
1105 cells and other intestinal cell lineages are highlighted. Rows show Z scores of normalized, \log_2 -
1106 transformed values from genes significantly changing ($p_{adj} < 0.05$) with a fold change cut-off >1 and <-1 .
1107 **b** Heatmap displaying enrichment of transcription factor motifs detected at accessible genomic locations
1108 (ATAC-sequencing data) that display significant dynamics of histone modification H3K27ac
1109 (ChIPmentation data, $p_{adj} < 0.05$) between RANKL-treated and control organoids. Only motifs of
1110 transcription factors differentially expressed ($p_{adj} < 0.05$) between RANKL-treated and control
1111 organoids from the bulk RNA-sequencing data are included. Rows show Z scores of motif enrichment
1112 with a cut-off of >1.64 and <-1.64 . **c** UMAP embedding of single cell transcriptome from RANKL-treated
1113 organoids. Each dot represents a single cell. Cell colours represent cluster identity. Next, highlighted on
1114 black the partitions corresponding to cell populations expressing markers of the absorptive or secretory
1115 lineages, or markers of intestinal stem cells (ISC) and transit-amplifying cells (TA). **d** UMAP embedding

1116 overlay showing the harvesting time points during differentiation. Next, normalized and natural log-
1117 transformed expression of *Id3*, *Lgr5* and *Mki67*. **e** Velocity projections on UMAP embedding coloured as
1118 in **c**. Below, normalized and natural log-transformed expression of top markers from cluster 17 (*Aldob*),
1119 cluster 12 (*Spib*) and cluster 3 (*Ccnb2*). **f** Heatmap showing row Z scores of regulon activity (area under
1120 the curve scores) averaged per each cell population as analysed by pySCENIC. On red, regulons of
1121 transcription factors for which an active motif was found in **b**. Group of interest 1 (GOI1) and 2 (GOI2)
1122 are shown.

1123

1124 **Fig. 3.** ONECUT2 signalling in M cell precursor cluster. **a** On the left, UMAP embedding overlay showing
1125 three partitions, group of interest 1 (GOI1), 2 (GOI2) and 3 (GOI3). On the right, top four transcription
1126 factors expressed within GOI1, with the highest positive correlation between transcript factor
1127 expression and motif activity. The logos for the motif of HNF4G (GM.5.0.Nuclear_receptor.0068), KLF5
1128 (GM.5.0.C2H2_ZF.0006), ONECUT2 (GM.5.0.CUT_Homeodomain.0005) and TCF7L2
1129 (GM.5.0.Mixed.0092) are displayed. **b** Gene-set enrichment analysis showing ONECUT1-, ONECUT2- and
1130 ONECUT3-specific gene signatures from Data ref: (48) enriched in RANKL-treated organoids compared to
1131 control organoids (dark grey). Normalized enrichment score (NES) and padj values are described.
1132 Signatures enriched in control compared to RANKL condition (light grey) have a negative NES. **c** Gene-
1133 regulatory network of *Onecut2* drivers predicted by ANANSE. Interaction scores (arbitrary cut-off ≥ 0.83)
1134 are depicted. **d** Trajectory plot overlaid with cluster identity of individual cells from RANKL-treated
1135 clusters in GOI1. Three major branches are shown along the plot. On the right, same trajectory plot with
1136 cells ordered along a pseudotime. Below, \log_{10} expression values of *Onecut2* and top genes from each
1137 branching point are shown. **e** Co-regulated modules of differentially expressed genes by cells from
1138 RANKL-treated clusters in GOI1. The transcription factors predicted by ANANSE as *Onecut2* drivers and









1139 ONECUT2 targets, that are differentially expressed (FDR < 0.05) by cells from RANKL-treated clusters
1140 within GOI1 and defined as pseudotime-dependent genes are highlighted.




1141


1142 **Fig. 4.** ONECUT2 restricts M cell lineage specification *in vitro*. **a** Bright-field images of organoids treated
1143 with RANKL, ONECUT2 inhibitor CSRM617 or a combination of both, and control organoids. Microscope
1144 magnification is depicted. Below, graph with organoid circularity quantification (AU, arbitrary units) and
1145 mean \pm SEM. Control n=40, CSRM617 n=35, RANKL n=33 and RANKL + CSRM617 = 70. **b** Heatmap
1146 showing the relative change in the mRNA expression of transcripts upon co-treatment with RANKL and
1147 CSRM617, compared to RANKL-alone. Rows show Z scores of normalized, \log_2 -transformed values from
1148 significantly changing genes (padj < 0.05). **c** Bar graph representing the mean \pm SEM of at least four
1149 differentiation experiments. Below, density plots depicting fluorescent intensities in FITC (LGR5) and PE
1150 (GP2) channels, determined by flow cytometry. Percentage of gated populations is described. **d** Gene-
1151 set enrichment analysis (GSEA) showing RANKL-treated cluster 12-specific gene signature, enriched in
1152 organoids treated as in **a**, compared to control. Dotplot shows the normalized enrichment score (NES,
1153 colour) and FDR (size). **e** Label transferring from RANKL-treated cell clusters within GOI1 to cells co-
1154 treated with RANKL and CSRM617. Bar graph on the right shows the fold change (FC) number of cells
1155 with RANKL clusters' identity (RANKL + CSRM617 over RANKL). **f** GSEA showing the HNF4G- and
1156 ONECUT-ChIP signatures, enriched in organoids growing in EN medium, compared to control medium.
1157 NES and padj values are described. **e** Relative mRNA expression of *Onecut2*, *Hnf4g*, *Klf5* and *Klf6*
1158 detected in organoids growing on EN medium alone or with RANKL. **f** Ratio of LGR5⁺ or GP2⁺ cell
1159 numbers in organoids growing on EN or control medium with RANKL or EN medium alone, over control
1160 conditions, determined by flow cytometry. Bar graph representing the mean \pm SEM of three
1161 differentiation experiments. For **b**, **c**, **e** and **f**, unpaired t test p < 0.05 is represented by (*), p < 0.01 by
1162 (**), and p < 0.001 by (***)).











1163

1164 **Fig. 5.** ONECUT2 regulates M cell number and mucosal immunity *in vivo*. **a** Immunohistochemistry
1165 analysis for GP2 and SPIB protein expression in Peyer's patches of small intestine sections from mice
1166 treated with PBS control or CSRM617 for 14 days. Nuclear counterstaining with hematoxylin (bright
1167 field) or DAPI (fluorescence) is shown. Scale bars are annotated. Dotted rectangles show amplified areas
1168 and yellow arrow heads show GP2⁺ cells. **b** RT-qPCR analysis showing relative mRNA expression of M-cell
1169 markers *Spib*, *Gp2* and *Tnfrsf25* in small intestine sections from mice treated as described in Additional
1170 file 1: Fig. S2d. Unpaired t test $p < 0.05$ is represented by (*) and $p < 0.01$ by (**). **c** Relative mRNA
1171 expression of ONECUT2-targeted genes *Klf5*, *Klf6*, *Hoxb8*, *Foxn3*, *Tfcp2l1* and *Hnf4g* detected in tissue
1172 from **b**. Unpaired t test $p < 0.05$ is represented by (*), $p < 0.01$ by (**) and $p < 0.001$ by (***). **d**
1173 Secretory IgA (SIgA) levels in faecal samples from mice treated as described in Additional file 1: Fig. S2d.
1174 Unpaired t test $p < 0.05$ is represented by (*). **e** Relative mRNA expression of markers from IgA⁺ B cells
1175 *Ccr9* and *Itgb7* detected in tissue from **b**.












a




b




d






c



e







c



c

AI987944	GATA3	MAFA	RFX7	ZFP326
ARNTL2	GATA4	MECOM	RUNX2	ZFP334
ARX	GLIS1	MECP2	SIRT6	ZFP354B
ATF7	GM4724	MEF2A	SIX1	ZFP449
AW146154	GRHL1	MEF2D	SMAD3	ZFP606
BACH2	GSX2	MRPL1	SOX12	ZFP704
BATF3	GTF2IRD1	MSX1	SOX15	ZFP708
BORCS8	HDAC3	MYBL1	SP2	ZFP729A
CBX3	HLF	MYBL2	SP9	ZFP74
CDX1	HMBOX1	NEUROD2	SPDEF	ZFP941
CERS6	HMGA1	NEUROG3	SPIC	ZFP950
CNOT3	HNF1A	NFATC2	SRP9	ZFP971
CREB3	HNF4A	NFIL3	STAT2	ZFP974
DBP	HOXB13	NHLH1	SUZ12	ZFP975
DMRTA2	HOXB8	NPDC1	TBR1	ZFX
DNMT3A	HOXB9	NR1D1	TCF24	ZKSCAN1
E2F7	HOXC11	NR1H3	TCF7	ZKSCAN7
E4F1	HOXC4	NR1I3	TEAD4	ZSCAN10
ELF3	HOXD13	NR2C2	TFAP2B	ZSCAN18
ELF5	IRF1	NRL	TFDP2	
ELK4	IRF5	ONECUT1	TFE3	
ERF	IRF6	OVOL1	TIMM8A2	
ESR1	IRF8	PAX2	TRIM28	
ESR2	ISX	PAX6	TRP73	
EVX1	JDP2	PBX1	TRPS1	
FOXD2	KDM4A	POLR3A	USF2	
FOXI1	KLF1	POU2F1	YBX1	
FOKK1	KLF10	POU3F2	ZBTB33	
FOKK2	LEF1	PRKAA1	ZBTB40	
FOXP3	LHX4	RARG	ZBTB7A	
FOXP6	LHX5	RB1	ZFP108	
FOXP3	LHX9	RFX6	ZFP319	



1 **Supplementary information**

2

3 **Additional file 1**

4 **Fig. S1.** RANKL-induced transcriptional and cellular responses *in vitro*. **a** Expression heatmap of top
5 10 markers per cell, for each cell cluster, expressed at least in 25% of the population and with a
6 natural-log fold change > 0.25, from the single-cell RNA-sequencing analysis of RANKL-treated
7 organoids. **b** EdU-labelled (proliferating cells) and LGR5⁺ cells in control organoids, and in those
8 treated with RANKL for 3, 6 and 9 days. Hoechst (nucleus) was used as counterstaining. Microscope
9 magnification is depicted. **c** Pseudotime trajectory plot overlaid with experimental time point
10 information of individual cells from RANKL-treated cell populations of the group of interest 1 (GOI1).

11 **Fig. S2.** Transcriptional responses to co-treatment with RANKL and CSRM617 *in vivo*. **a** Heatmap
12 showing the relative change in the mRNA expression of transcripts upon co-treatment with RANKL
13 and CSRM617, compared to RANKL-alone, CSRM617 alone and control conditions. Rows show Z
14 scores of normalized, log₂-transformed values from significantly changing genes (padj < 0.05). **b**
15 UMAP embedding of single cell transcriptome from RANKL and CSRM617 co-treatment in organoids.
16 Each dot represents a single cell. Cell colours represent cluster identity. **c** Venn diagram with
17 regulons in the single-cell RNA-sequencing dataset of RANKL-treated organoids and that of
18 organoids co-treated with RANKL and CSRM617. Treatment-specific regulons are listed and ONECUT
19 target genes are highlighted on red. **d** Work plan for *in vivo* experiments with ONECUT2 inhibitor
20 CSRM617. Four treatment groups were designed: One group of mice treated with 50 mg/kg-1
21 CSRM617 for 7 days (n=6) and another group for 14 days (n=6), a recovery group consisted of mice
22 treated with 50 mg/kg-1 CSRM617 for 7 days followed by 7 days treatment with phosphate
23 buffered saline (PBS) and 0.2% dimethyl sulfoxide (n=6), and a control group treated with PBS and
24 0.2% DMSO for 7 days (n=6). **e** RT-qPCR analysis showing relative mRNA expression levels of *Dclk1*,

25 *Defa6* and *Reg4* in small intestine sections from mice treated as described in **d**. **f** Body weight of
26 mice treated as described in **d**.

27 **Additional file 2**

28 **Table S1:** Top differentially expressed genes for each cell population (cluster) in the single-cell RNA-
29 sequencing dataset from RANKL-treated organoids.

30

31 **Table S2:** List of transcription factor-motif combinations with the highest positive correlation
32 coefficient between transcript expression and motif activity (FDR < 0.1) in the single-cell RNA-
33 sequencing dataset from RANKL-treated organoids, generated by SCEPIA.

34

35 **Table S3:** List of genes constituting the KLF5, ONECUT2, TCF7L2 and HNF4G gene-regulatory
36 networks derived from the ANANSE-generated differential gene-regulatory network of RANKL-
37 treated organoids over control.

38

39 **Table S4:** Gene set enrichment analysis with ONECUT1-, ONECUT2- and ONECUT3-specific signatures
40 in RANKL-treated organoids.

41

42 **Table S5:** Differential ONECUT2 binding determined by ChIPmentation and nearest genes.

43

44 **Table S6:** Composition of the regulons corresponding to the transcription factors predicted by
45 ANANSE as drivers of *Onecut2* transcript expression.

46

47 **Table S7:** Pseudotime-dependent transcription factors within RANKL-treated cell populations of
48 groups of interest 1 (GOI1) in the single-cell RNA-sequencing dataset from RANKL-treated organoids.

49

50 **Table S8:** RT-qPCR primers used for the detection of *Onecut2*, ONECUT2-target genes *Hnf4g*, *Klf5*,
51 *Klf6*, *Hoxb8*, *Foxn3* and *Tfcp2l1*, M cell markers *Spib*, *Gp2* and *Tnfaip2*, other small intestine cell types
52 like *Dclk1*, *Defa6* or *Reg4*, and IgA+ B cell markers *Ccr9* and *Itgb7* in mice small intestine tissue of
53 mice treated as in Additional file 1: Fig. S2d.